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STATEMENT OF PROBLEM 
This work focuses on the development of selectivity information and applied 
methods for the use of a novel chromogenic reaction based on the Chugaev reaction. The 
emphasis is placed 011- quantitative comparisons of reactions with various analytes and 
quantitation of analytes related to the determination of unsaturated lipids in sera. 
The use of color forming reactions with organic molecules has been an important 
part of analytical and medical science. These reactions have allowed the analysis of a 
variety of compounds found in living systems. Modem colorimetric reactions for the 
analysis of biological analytes often involve enzymatically-catalyzed reactions. The 
accuracy of chemical methods, however, often make them the standard methods of· 
analysis by which the enzymatic systems are evaluated. 
The reaction used in this study was first disclosed in 1995.1 It consists of a 
reaction conducted at ambient temperatures that is known to be chromogenic with a 
variety of analytes. The reaction was further characterized to be reactive with 
polyunsaturated fatty acids (PUFA).2 At that time, the working hypothesis was that the 
reagent reacted with a variety of unsaturated carbon systems. 
The reaction was shown at the time of its disclosure to be quantitative for 
cholesterol. The ability to quantitate cholesterol is a characteristic of a variety of 
chemical reactions. The most common chemical reaction for the quantification of 
cholesterol is the Liebermann-Burchard (L-B) reaction. It was of interest to determine 
the relationship between the current chromogenic assay and the L-B reaction to 
understand the differences and benefits of the current assay. 
1 
Chapter I addresses the question of what spectral response and what potential this 
reaction has to selectively quantitate alternative double bond containing compounds. The 
analytical potential for this reagent in the analysis of various compounds relies on 
understanding these reaction properties. A variety of analytes was tested to this end 
primarily in the steroid, terpene, and PUF A categories. Also tested were small 
unsaturated organic compounds. All of the reactions were conducted at stoichiometric 
equivalence (where possible) in order to quantitatively compare the spectral response of 
the analytes. The relationship between the chemical reaction presented with the L-B 
reaction was considered by conducting chemical reactions with identical analytes using 
both reagents. 
In Chapter II, the use of the chemical assay to simultaneously determine 
concentrations of analytes in mixtures using multivariate analysis is explored. Synthetic 
mixtures were prepared as models to allow the development and further refinement of 
methods to the goal of a routine, reliable assay not requiring separations or other sample 
pretreatments. Combinations of PUF A and cholesterol mimicking the proportions found 
in human sera were made and analyzed using multi-linear regression (MLR) in order to 
test the feasibility of applying multivariate analysis on real samples. 
Also considered in Chapter II is the ultimate goal for the chemical assay to be 
used in the routine clinical analysis of patients' sera. It is believed that the assay's 
chemical stability, low cost per assay and ability to determine alternative PUF A 
information can position the reaction as a viable alternative routine assay in the future. 
A literature review is presented outlining the current routine clinical analysis 
methods. Also demonstrated is the dynamic nature of the lipids analysis field and 
2 
discussion of some developing analytical methods is made. Finally, a summary of the 
information in the literature on the importance of PUF A profiles in human disease 
demonstrates the potential importance of this new assay to the clinical physician. Special 
emphasis is placed on the quantification of PUF A profiles and the determination of 
conjugated dienes as ah indicator of oxidative stress. 
Finally in Chapter II, the use of the chemical reagent in clinical settings was 
demonstrated when a dyslipidemic patient was monitored over the course of a dietary 
intervention. This study demonstrated the utility of the reagent in its current (relatively 
undeveloped) form. A direct comparison between the current standard methods used in 
routine clinical analysis and the chromogenic reaction was made when the multivariate 
method developed for the analysis of synthetic mixtures was used for the analysis of the 
case study sera. 
The results presented in this work add to the developing information about this 
convenient, low cost, robust chemical assay. It adds to the pure and applied scientific 
knowledge needed to bring the assay to application. 
3 
CHAPTER I 
CHROMOGENIC REACTIONS OF MODEL COMPOUNDS 
One of the oldest and most commonly used color forming reactions is the L-B 
reaction. The Liebermann reaction was first used in the 19th century,3 and was later 
applied to cholesterol by Burchard, thus becoming known as the L-B reaction.4 The L-B 
reaction uses sulfuric acid with acetic anhydride in the presence of acetic acid. Another 
commonly used reaction for the determination of cholesterol is the Zac reaction.5 
Similarly, the Zac reaction takes advantage of the same acetic acid and sulfuric acid 
solutions, while utilizing ferric ions (Fe3+) in place of the acetic anhydride. The Fe3+ is 
required for the reaction to occur.6 An alternative chromogenic reaction is the Chugaev 
reaction. In the Chugaev reaction, the acetic anhydride is replaced by acetyl chloride 
while the other component of the reaction mixture is zinc chloride. Unlike the L-B 
reaction, the Chugaev reaction requires heating to facilitate the chromophore production. 
Studies on the mechanisms of strong acid cholesterol reactions such as the L-B and Zac 
reactions usually mention the Chugaev reaction. The Chugaev reaction actually seems to 
be a unique reaction that can, in a modified form, react in selective ways with unique 
analytes at room temperature. 
The mechanism of the strong acid cholesterol reactions has been studied for some 
time. The area is practically dormant currently as strong evidence has led to mechanisms, 
which are adequate for the current applications. When strong acids such as perchloric or 
hexafluorophosphoric acid are added to an organic solution of cholesterol in equivalent 
stoichiometric amounts a "colorless sterolium salt" forms. If the acid is added in excess 
4 
the "colorless sterolium salts" form a purple colored solution of "salts of cholestadiene".7 
It was eventually hypothesized that this acid reaction involves cholesterol undergoing 
dehydration to form 3,5-cholestadiene and 2,4-cholestadiene that then forms the dimers 
(1) 3-3'-bis-3,5-cholestadiene and (2) 3,3'-bis-2,4-cholestadiene.8 Other studies 
substantiated this hypothesis, and the L-B reaction was believed to also involve this 
dehydration of cholesterol followed by the formation of dimers.9• 10 Eventually the dimer 
hypothesis was proven with the isolation of 3,3'-bis-3;5-cholestadiene.8 The 2,4 dimer 
(2) was found in the reaction mixtures of the L-B, Zac and Chugaev reactions.8• 11• 12 The 
presence of the dimer(s) does not preclude other significant product formation. 
Later research proposed the· formation of an extended conjugated system within 
the ring structure of cholesterol, rather than the dimer, as the primary absorbing product. 13 
Much later the L-B reaction product was substantiated as an extended conjugated ring 
structure by Burke.6 Burke monitored the production of sulfur dioxide during the L-B 
reaction to calculate the chromophore structure produced. Dulou also measured sulfur 
dioxide production in the L-B reaction and found results in agreement with Burke's 
conclusions.6• 9• 14 
Along with the controversial nature of the area of strong acid cholesterol color 
reaction mechanisms, later reports supported the dimer hypothesis. The dimer formation 
reaction requires the presence of a species to accept the freed hydrogen. In the case of 
the TCA-HCl (1:1) reaction, the absence of oxygen prevented the dehydration from 
occurring, 15 therefore preventing the production of the dimer. The reaction does produce 
3,5-cholestadiene, cholesteryl chloride, and cholesteryl trichloroacetate. The absorbance 
spectrum is missing the 560 nm peak that is said to be -the dimer.16 It would be logical to 
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consider that the dimer would form if a "hydrogen acceptor" were in solution. The 
authors used oxygen and hydrogen peroxide as the hydrogen acceptor and found the 
dimer forms with oxygen. The structure hypothesized by Burke. 6 was not isolated in this 
reaction. 15 
While the mechanism and active product of the strong acid reactions are not fully 
· understood, the activity and analytical utility of these reagents are well known. The L-B 
reaction is currently the Center for Disease Control (CDC) standard chemical cholesterol 
determination method. Throughout development of the modem enzymatic cholesterol 
determination methods, the new systems have been compared to the Abell-Kendall 
method. The Abell-Kendall method is the CDC standard, which uses transesterification 
lipid isolation of the cholesterol from human plasma samples and the L-B reaction for 
quantification.17 The L-B reaction is also routinely used in modem research laboratory 
analysis and method development. 18 
Introduction to Model Compounds 
The model compounds are composed of three major classes: fatty acids, steroids, 
and terpenes. Each will be considered as independent groups and finally cross class 
correlations will be summarized. 
Steroids 
The steroid compounds are all based on the cholesterol ring template and are 
structurally unique. The analysis of steroids is a widely used process by industries 
including agriculture, medicine, forensic, and nutritional sciences. 19•24 Many of the 
steroids considered are physiologically relevant to mammals. 
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The nomenclature used in the description of steroids is specialized. It uses a 
specific carbon numbering system and ring designation to define the structural features. 
The cholestane skeleton numbering system is as follows: (Figure 1) 
2 
3 
21 22 24 
23 
6 
Figure 1. Steroid carbon numbering and 
ring designations. 
26 
There are 26 steroids in this study. They include cholesterol and its derivatives 
including cholesteryl chloride. Cholesterol (Figure 2(A)(R=H)) has a hydroxide on 
carbon 3 and an unsaturation at carbon 5 while cholesteryl chloride (Figure 2(A)(Cl on 
carbon 3)) has a chloride at carbon 3 and the double bond at carbon 5. There were ester 
derivatives of cholesterol including cholesteryl oleate, cholesteryl nonanoate, cholesteryl 
myristate, cholesteryl acetate, cholesteryl linolenate, and cholesteryl linoleate. These 
compounds have an additional carbon chain attached as an ester of the hydroxide on 
carbon 3 (Figure 2(A)(R=COR)) 
Other steroids tested are stigmasterol (Figure 2(B)), dihydrocholesterol (Figure 
2(C)), 7-dehydrocholesterol (Figure 2(D)), alpha-estradiol (Figure 2(E)), beta-estradiol 
(Figure 2(E)), ergosterol (Figure 2(F)), stanozolol (Figure 2(G)), norethynadrel (Figure 
2(1)), diosgenin (Figure 2(J)), testosterone (Figure 2(K)), 17-alpha-methyl testosterone 
(Figure 2(L)), 4-cholesten-3-one (Figure 2(M)), 5-cholesten-3-one (Figure 2(N)), 5-
7 
cholesten-3-beta-ol-7-one (Figure 2(0)), progesterone (Figure 2(P)), prednisone (Figure 
2(Q)), hydrocortisone (Figure 2(R)) and prednosilone (Figure 2(S)). 
Terpenes 
The terpenes are polymers of the isoprene unit (CH2=C(CH3)-CH=CH2). They 
are found mostly in plants. Some of them are important in human physiologically such as 
vitamin Al. The synthesis of terpenes commonly includes cyclization of the isoprene 
polymers to form commonly found ring structures. The terpenes, in fact, can be 
subdivided into those with linear structures and those with cyclic structures. They will be 
presented in this study as two separate groups. The linear terpenes will also be presented 
with other small organic model compounds that are not terpenes. 
The small organic model compounds are 1,4-pentadiene, trans-1,3-pentadiene and 
cis-1,3-pentadiene (Figure 3) The linear terpenes are myrcene, squalene and farnesol 
(Figure 3). Limonene, S-(+)-carvone, alpha-pinene, beta-pinene and camphene comprise 
the cyclic terpenes (Figure 3) 
Polyunsaturated Fatty Acids 
Fatty acids in the context of this work are all methyl esters. The fatty acids have 
varying degree of unsaturation. The natural forms of fatty acid unsaturations are 
methylene bridged so that the unsaturated fatty acids can be represented as (-
. CH=CHCH2-)n polymers at the double bond containing region. The degree of 
unsaturation is determined by both dietary and metabolic modification (see Chapter I) . 
. The location of the unsaturated region is also physiologically important (see Chapter I). 
The nomenclature for lipids has many variations summarized in Table 1. 
8 
Table 1. Description of polyunsaturated fatty acid structures. 
Name Total Double bonds Double bond Omega 
Carbons locations number 
Oleate 18 1 9 9 
Linoleate 18 2 9,12 6 
Conjugated 18 2 10,12 6 
Linoleate 
Linolenate 18 ~ 9,12,15 3 .) 
Arachidonate 20 4 5,8,11,14 6 
Eicosapentaenoate 20 5 5,8,11,14,17 3 
Docosahexaenoate 22 6 4, 7 ,l 0, 13, 16, 19 3 
9 
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Figure 2. Steroid structures. 
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Experimental Methods 
The experimental methods used in this study are based on the reaction of acetyl 
chloride (AC) with unsaturated compounds and a catalyst. The analytes include steroids, 
terpenes, fatty acids and small organic compounds. The reaction was discovered during 
investigation of Chugaev reaction for cholesterol.25 The original Chugaev method was 
problematic due to a procedure that involves heating the analytes in AC with ZnCli. The 
modified method, presented here, involves the use of an alternative catalyst such as 
perchloric acid (PA), zinc acetate, or zinc perchlorate.1 With these alternative catalysts 
the reaction occurs at ambient laboratory conditions. The reaction is also convenient, as 
the reaction is initiated by the addition of catalyst and analysis of complex samples such 
as human serum can be done without pretreatment. The reaction with serum results in the 
precipitation of protein upon the addition of catalyst. This may occur due to the 
acetylation of the proteins to less soluble forms. The resulting precipitate is easily 
removed by centrifugation or filtration. The absence of the requirement for pretreatment 
is commercially significant as sample analysis times are shortened. 
This new reagent has been used for the determination of total cholesterol (TC) by 
measuring the absorbance at 520 nm. It has also been used for the determination of the 
high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-
C), and very low-density lipoprotein cholesterol (VLDL-C) concentrations by single 
spectra multivariate analysis. 1 The reactivity of unsaturated fatty acids was demonstrated 
in the early twenty first century.2 This information was used in the theoretical 
recognition of dyslipidemias by spectral comparison. 
12 
The reagent is currently composed of 1.0 mL of 98% AC and 40 µL of 70% PA 
or 0.1 g solid catalyst. The most commonly used solid catalyst is zinc acetate. All 
reagents were from Sigma-Aldrich. The utilization of 40 µL of perchloric acid 
introduces 12 µL water into the AC. The reaction of AC with water produces HCl and 
acetic acid. This reaction occurs in the absence of catalyst. Zinc acetate is a dihydrate 
salt that is soluble in AC. The total water in 0.1 g of Zinc acetate is 1.6 times the water in 
40 µL PA. This is problematic, as the reaction products with water are known to be 
inhibitory to the reaction. The advantage of zinc acetate is that it is a stable non-
hygroscopic salt, which could be pre-weighed for automated high throughput analyses. 
An earlier procedure for the acetylation involved the use of dichloroethane (DCE) 
in the AC as a diluent. The resulting reaction was milder than the reaction with pure AC. 
DCE, however, does not increase the selectivity or sensitivity of the reagent and it is 
toxic and difficult to remediate. DCE seems to have the effect of lowering the 520 nm 
peak. Therefore, the preferred reagent uses pure AC. 
Reaction of Pure Compound with Perchloric Acid Catalyst 
Analysis is conducted by adding 10 µL of analyte solution to the bottom of a 13 X 
100 mm borosilicate disposable test tube. Pure AC (1.0 mL) is added to the analyte. The 
reaction is initiated when 40 µL PA is added to this mixture. The reaction timer is started 
immediately after addition of catalyst. The reaction is energetic thus caution should 
taken to slowly add the PA. The reaction is mixed by hand vortexing for 20 seconds and 
then either placed in a Teflon 10 mm pathlength cuvette for kinetic determination over 20 
minutes or allowed to mature inside the test tube to later be analyzed at the 15-minute 
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endpoint. Following maturation in the test tube the solution is transferred to the 10 mm 
pathlength cuvette with a glass Pasteur pipette and full spectral data (350-800 nm) are 
collected. 
Spectrophotometric Determination of Reaction 
Absorbance data of the colored products after the reactions were determined on a 
HP8452a Hewlett Packard spectrophotometer. A 5 second integration time and a 2 nm 
resolution were used. The blank for each reaction was the reagent (AC) without catalyst. 
The reagent once mixed with catalyst produces some coloration in the absence of analyte 
over the 20-minute reaction period. Since the coloration was small, varied, and did not 
necessarily produce equal amounts with and without analyte, the blank did not include 
this contribution. For future analytical applications of this reagent, the aforementioned 
considerations must be addressed in a rigorous way and an appropriate compensating 
solution implemented. 
Rate curves were calculated usmg standard software onboard the 
spectrophotometer.· The data were collected from 350 to 800 nm for each spectral 
collection. The usual spectral range of importance for the analytes in this study was from 
350 to 650 nm. There are 150 data points in the spectra from 350 to 650 nm. 
Absorbance data were automatically recorded every minute for 20 minutes. Any data 
between the addition of catalyst and completion of data preparation were lost at the 
beginning of the reaction. The resulting data were a 20 X 225 element matrix. It was 
found that the kinetics of the reaction demonstrates significant information about the pure 
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compounds, and may prove useful for the quantification of the known analytes m 
mixtures. 
Model Compound Calibration Data 
Calibration curves were done in duplicate with a minimum of 14 concentration 
data points per analysis. The calibration data were comprised only of the 15-minute 
spectra for each of the concentrations on the curve. Molar extinction coefficients were 
determined for 2-3 of the maxima in the spectra. Average data for each analyte were 
collected by repeated spectral determination. Using the molar extinction coefficient 
from the calibration curves, the best fit to the average spectra was made in order to 
determine the molar extinction coefficient at every wavelength. The resulting graph 
contained the molar extinction coefficient for the compound determined at the 
wavelength at which the calibration curve was obtained and extrapolated to all other 
wavelengths in the spectral range. 
Calibration curves were linear from 0.05-0.90 absorbance units with R-squared 
values in the range of 0.980 or better. The maximum molar absorptivity values for the 
model compounds analyzed were from 250-9000 Absorbance units per mole. The 
highest absorptivities were found in the conjugated dienes in linear carbon systems and in 
cholesterol. Limits of detection were determined for a subset of model compounds and 
are in the order of0.01-0.08 mM. 
Fatty acids 
Analyte stock solutions were either 0.02 M or 0.01 M in spectroscopic grade 
chloroform (Aldrich) depending on the molar extinction coefficients. For an analysis, 10 
15 
µL of the stock analyte is used in the reaction the chosen reagent. A total of 2.0 x 10-7 
moles of analyte is all that is needed for each analysis. All of the PUF As are prone to 
autoxidation and were stored under argon, at less than 0°C, and kept from light. 
Liebermann-Burchard Reagent Preparation 
The L"'.'B reagent was made by addition of ice cold 20 mL acetic anhydride and 1.0 
mL of ice cold concentration sulfuric acid. The mixture was stirred for 10 minutes on 
ice. To the cold mixture, 10 mL of acetic acid was added and the mixture was allowed to 
come to room temperature. 
Liebermann-Burchard Reaction 
The L-B reaction was conducted by the addition of 50 µL of analyte dissolved in 
chloroform (0.02 M) to a 13 X 100 mm borosilicate disposable test tube. To the analyte 
1.0 mL of L-B reagent was added. The reaction timer was started immediately after the 
addition of the L-B reagent. The reaction was allowed to occur for 30 minutes. The 
sample was then transferred to the Teflon sealed 10 mm cuvette using a glass Pasteur 
pipette. The sample was analyzed by UV Nisible spectrophotometry at 30 minutes into 
the reaction from 350 to 800 nm. A catalyst is not required. The final color of the 
reaction is blue-green. 
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Results and Discussion 
Steroids 
Steroids with 5-ene-3-P-substituents (cholesteryl esters) 
A common physiological derivative of cholesterol involves esterification of a side 
chain at the 3-beta hydroxide. The reagent is effectively blind to the ester and leads to 
spectrum practically identical to cholesterol (Figure 3(C)). The cholesteryl esters are 
important in the hydrophobic transport of cholesterol (Figure 2(A)(R=H)). For all esters 
that have saturated chains, the spectra were very similar including cholesteryl nonanoate 
(Figure 3(D)), cholesteryl myristate (Figure 3(E)), and cholesteryl acetate (Figure 3(F)). 
Cholesteryl oleate (Figure 3(B)) has the monounsaturated oleate fatty acid attached at the 
3-beta ester. The spectrum indicates a similar electronic spectrum over all wavelengths 
below 550 nm. The contribution of oleate at 0.02 M should be very small in the short 
wavelength range and not affect the region around 520 nm. All of the cholesteryl esters 
have a maximum absorbance at 360 nm, 420 nm, and 520 nm with the 520 nm peak 
having the largest absorptivity. 
The final · cholesteryl ester compounds considered were those with 
polyunsaturated ester linked side chains. These include cholesteryl linoleate (Figure 
4(B)) and cholesteryl linolenate (Figure 4(A)). For these cholesteryl compounds the 
spectrum is not equal to that for cholesterol (Figure 4(C)). It would be expected that the 
linoleate and linolenate functional double bonds would react to form a spectrum similar 
to the methyl esters of linoleate (Figure 4(E)) and linolenate (Figure 4(D)). In fact when 
the 0.01 M spectra for methyl linoleate and linolenate are subtracted from the cholesteryl 
linoleate and linolenate respectively, the resulting spectra (Figure 4(insert: G,H)) are very 
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similar to that of cholesterol (Figure 4(insert)(C)). It is not clear why there is a consistent 
rise in the 520 nm region and lowering in the shorter wavelengths. The spectra are the 
same within experimental errors. 
One compound with a non-ester substitution at the 3-J3 position was considered. 
Cholesteryl chloride (Figure 3(A)) has chloride as an alternative functional group in place 
of the hydroxide. The chloride at the 3-J3 position alters the resulting spectrum by 
increasing the overall absorptivity at all wavelengths and shifting the maximum 
absorbance from 520 nm to 514 nm. 
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Figure 3. Overlaid spectra of cholesterol derivative including A) cholesteryl 
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3-J3-ol 5-ene compounds 
Cholesterol has 3-J3-ol and 5-ene functional groups. Three other compounds 
share these exact functional groups. They are diosgenin (Figure 5(A)), 5-cholesten-3-P-
ol-7-one (Figure 5(B)), and stigmasterol (Figure 5(C)). Comparing the resulting spectra 
and the steroid structure that produced them, the spectrum for diosgenin is significantly 
· different from those for the other cholesterol like compounds. 
Diosgenin only varies structurally at the 17th carbon were there is added ring in 
place of the aliphatic chain of cholesterol (Figure 2(1)) The electronic spectrum of 
diosgenin has a broad peak with maximum at 420 nm. The spectrum extends from 350 
nm out to 650 nm with several underlying maxima present. Differential analysis shows 
the maxima at 362, 396, 420, 444, 498, and 570 nm. The spectrum is completely 
different from cholesterol with significant broadening and obvious lack of the 520 nm 
peak. There is no obvious explanation for this result. 
5-cholesten-3-J3-ol-7-one is structurally different from cholesterol in the active 
area (Figure 2(0)). The added ketone is in close proximity to the active unsaturated 
region on carbon 5. It is not clear how the ketone effects the reaction in terms of the 
product formed, however, the spectral differences are significant (Figure 5(B)). The 
spectrum shows a maximum at 444 nm, a large absorbance in the short wavelength past 
350 nm and a small absorbance at 526 nm. The conjugated ketone formed by the 
addition of the ketone to carbon seven has been reviewed in a number of compounds 
addressed later. 
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Stigmasterol only varies from cholesterol at the 17 carbon aliphatic chain (Figure 
2(B)). The side chain has an unsaturation at the 19th carbon and an ethyl group at carbon 
21. Knowing the double bond is cis for stigmasterol, we can best correlate the double 
bond to methyl linolelaidate (Figure 15(A)). In both cases, the absorption at 420 nm is 
increased. Stigmasterol also has another larger absorbance at 404 nm. This larger 
absorbance makes the 420 nm absorbance a distinguishable shoulder. Furthermore, 
stigmasterol has a 362 nm peak similar to cholesterol except with a larger absorbance. 
Stigmasterol has almost exactly the same absorbance at 520 nm as cholesterol at equal 
molarity. Finally, there is an absorbance at 594 nm that is unique to stigmasterol among 
the 3-P-5-ene compounds. 
Other Steroid Compounds 
Another compound tested containing sterol skeletons 1s dihydrocholesterol. 
Dihydrocholesterol is composed of exactly the same carbon framework, as cholesterol 
except it does not have the 5,..carbon unsaturation (Figure 2(C)). The reaction of 
dihydrocholesterol results in no appreciable color formation (Figure 6(F)). Another 
compound tested also did not undergo chromogenesis with the AC reagent was P-
estradiol. Alpha and P-estradiol are both composed of a sterol skeleton with an aromatic 
benzene-like structure on ring A (Figure 2(E)). No spectral response was seen after 
reaction with the acetyl reagent (Figure 6(E)). 
While P-estradiol gives no coloration upon reaction, a-estradiol forms one of the 
most intense spectra of the sterols examined (Figure 6(A)). The spectrum includes a 
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weak broad absorbance around 384 run with an intense absorbance at 512 run. There is 
also a shoulder to the largest peak around 454 run. The two differ only in the 
enantiomeric orientation of the 17-hydroxide. The variation of response between the two 
compounds is profound. 
7-dehydrocholesterol has the same structure as cholesterol except there is an 
additional unsaturation at carbon-7 (Figure 2(D)). This second unsaturation produces a 
conjugation double bond in ring B of the sterol backbone. The resulting spectrum shows 
a large absorption at 392 run and a smaller absorption that seems to split with minima at 
486 run and 508 run (Figure 6(C)). Ergosterol has the same structure as 7-
dehydrocholesterol except it has an unsaturation on carbon-19 and a methyl group off 
carbon-21 (Figure 2(F)). The unsaturation and hydroxide configuration are exactly 
equivalent in the first two rings (A and B) of the structures. The double bond on the side 
chain has a trans conformation. It is therefore similar to methyl oleate. The spectrum for 
ergosterol is similar to that of 7-dehydrocholesterol except there is an increase in the 
absorbance and there is an overall broadening of the spectrum (Figure 6(B)). The 
maximum absorbance is at 388 run and 486 run. There is a significant tail beyond 570 run 
extending out to 800 run. 
Stanozolol has a unique structure with a nitrogen heterocycle fused to ring A of 
the sterol skeleton (Figure 2(G)). It has a 17-hydroxyl similar to the estradiols 
spectroscopically stanozolol has a relatively simple spectrum (Figure 6(D)). It has a 
single broad peak around 394 run. 
24 
1.2 
A 
1.0 
CJ) 0.8 
0 
C 
cu 
.c 0.6 .... 
0 
u, 
.c 
<( 0.4 
0.2 
0.0 
350 400 450 500 550 600 650 700 750 
Wavelength (nm) 
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Compounds with Cortjugated 3-ones 
A number of compounds have the hydroxide at the 3-carbon of cholesterol 
replaced by a ketone. In a majority of the sterols considered in this study, the ketone is 
accompanied by an unsaturation at the 4-carbon forming an unsaturated ketone on ring A. 
Testosterone is a good example of this type of compound. Testosterone is a 4-ene-3-one 
structure with a 17-hydroxide (Figure 2(K)). The spectral response for testosterone is 
comprised of a large absorption at 368 nm (Figure 8(C)). The spectrum of testosterone is 
very simple. Other 4-ene-3-one compounds are more complex in their spectral response. 
5-cholesten-3-one is very different structurally from testosterone (Figure 2(N)). The 3-
position ketone is no longer conjugated as the unsaturation is at the 5 carbon as is the 
case with cholesterol. The spectral response includes a maximum absorbance at 372 nm 
and a smaller absorbance at 526 nm (Figure 7(C)). There is little similarity between 5-
cholesten-3-one and testosterone. There are more structural similarities between 4-
cholesten-3-one and testosterone (Figure 2(M)). The spectrum of 4-cholesten-3-one 
includes a maximum at 372 nm and a smaller peak at 526 nm the same as 5-cholesten-3-
one (Figure 7(D)). Both 4-cholesten-3-one and 5-cholesten-3-one have the aliphatic 
group from cholesterol on the carbon-17 position. This difference may contribute to the 
lack of similar spectra in the 4-cholesten-3-one and testosterone. 
Another 4-ene-3-one compound is progesterone. Progesterone is the same sterol 
structure as testosterone except the 1 7- position has an a ketone ethyl group in place of 
testosterone's hydroxide group (Figure 2(P)). Progesterone has a maximum absorbance 
at 368 nm just like testosterone with almost the same molar extinction coefficient. 
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Progesterone also has a small broad absorbance in the longer wavelength around 590 nm 
(Figure 7(B)). The absorption at 590 nm may be due to the 17-ethyl ketone group. 
Hydrocortisone is also a 4-ene-3-one containing compound. Hydrocortisone is 
more highly substituted than the other 4-ene-3-one compounds. It has a hydroxide on 
ring C and at the 17- position, there is a hydroxide and a ketone ethanol group (Figure 
2(R)). The spectral response for this compound involves an absorbance at 366 nm 
reduced in size from the corresponding absorbance in testosterone (Figure 7(E)). It is 
common in these reactions that hydroxides react to lower absorbance of unsaturated 
groups. This is best illustrated by the fact that small alcohols can act to prevent the 
reaction all together. 
Testosterone can be modified so its 17-~-hydroxyl group is bonded to the same 
carbon as an enantio-specific carbon (Figure 2(L)). This 17-a-methyl forces the 
hydroxide to be alpha. The response to 17-a-methyl testosterone includes the absorbance 
at 368 nm with almost exactly the same extinction coefficient, and a number of 
absorbances not found in testosterone (Figure 8(B)). These 17-a-methyl testosterone 
specific absorbances include 496, 580, and 620 nm forming a significant absorbance in 
the longer wavelength range. 
3-one compounds 
Norethynadrel has a carbon-3 ketone and a double bond between ring A and ring 
B (Figure 2(1)). Instead, it has a double bond between ring A and B. Further 
complicating the structure, the 17 position has a hydroxide and ethyne group attached to 
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it. The spectral response for norethynadrel includes a peak at 384 run with a shoulder at 
426 run (Figure 8(A)). Norethynadrel also has absorbances at 520 and 584 nm. 
Double Conjugated 3 Ketone 
Two of the sterol compounds have unsaturations at the 1 and 4 carbons with a 
ketone at the 3- position. This forms a double unsaturated ketone compound. Prednisone 
and prednisolone are structurally similar to hydrocortisone except the double bond on 
carbon-I for prednisolone and prednisone and the ketone in place of the hydroxide on 
ring C for prednisone (Figure 2(Q and S)). The absorbance spectra of both prednisone 
and prednisolone are baseline (Figure 8(D and E) ). 
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Terpenes 
The calibration plots for terpenes are linear between 0.05 to 1.2 mM. The 
correlation coefficients for the Beers' law plots are for example 0.987 for a-pinene at the 
390 nm maxima. The correlations for farnesol are 0.988 at 386 nm, and 0.991 at the 486 
nm maxima. The limits of detection are in the order of 1. 0 x 10-5 M. 
Linear Model Compounds 
Pentadienes 
Included are non-terpene compounds such as 1,4-pentadiene, trans 1,3-pentadiene 
and cis 1,3-pentadiene (Figure 9. Trans 1,3-pentadiene, cis 1,3 pentadiene and 1,4-
pentadiene all have very similar spectra (Figure lO(E,F,G)). They all have single maxima 
at 412 nm. All three also have monotonic kinetics leading to the 15 minute maximum. 
There is a shoulder at 495 nm for all three pentadienes and the appearance of a minimum 
around 360 nm for the two 1,3-pentadienes may indicate an absorbance below 350 nm. 
Trans 1,3-pentadiene is 0.075 absorbance units higher than cis 1,3-pentadiene at 
412 nm at the 0.02 M stock concentrations. This difference can be related to the 
absorbance difference between methyl linoleate and methyl linolelaidate fatty acids. This 
may indicated that the cis I trans conformation of the 1,3-pentadienes does affect the 
resulting spectrum. However the conjugation in the double bonds of the two 1,3-
pentadienes would be analogous to conjugated methyl linoleate. The conjugation in 
methyl linoleate leads to a large increase in the resulting absorptivities and large variation 
in the kinetics of the reaction in the 422 nm region compared to methylene bridged 
linoleate. Furthermore, the large absorptivity of the product with conjugated methyl 
31 
linoleate is not formed in the reaction with a terminal double bond (1,3-pentadiene ). 
Therefore, the difference in the conjugated double bonds between the pentadienes and the 
conjugated methyl linoleate is the absence of a peripheral saturated carbon. It has been 
hypothesized in this laboratory that the reaction requires a local methylene (CH2) ( or 
possibly methyl) group in order to proceed. This hypothesis is supported by the 
pentadiene data. 
The 1,4-pentadiene does have a centralized methylene CH2 group yet it produces 
almost identical spectral features as the 1,3-pentadienes. This similarity of spectral 
responses is not likely due to double bond rearrangement of the 1,4-pentadiene into 1,3-
pentadiene configuration. If this type of rearrangement were a feature of this reagent 
system it would occur in the methyl linoleate and I or conjugated methyl linoleate 
systems. It is however, possible that the terminal double bonds are susceptible to 
rearrangement. In the case of three pentadienes, it is illogical to assume that the 1,4-
pentadiene with two terminal double bonds should have the same absorbance as the 1,3-
pentadienes with only one terminal double bond. Future work should include the analysis 
. of short double bond systems to elucidate the reaction mechanisms and products. 
Another point can be made from the reactions with small double bond containing 
compounds such as the pentadienes. The reaction mechanism hypothesis involving the 
buildup of a carbon structure from the double bond system is supported in these reaction 
as there is no possibility of the standard strong acid cholesterol reaction hypothesis 
involving dehydrogenation to create conjugated unsaturations any larger than already 
exist on the small molecules. The occurrence of the chromogenic reaction with the 
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pentadienes is strong evidence toward a mechanism for the reaction that involves an 
alternative mechanism than the acid reactions currently used in sterol determination. 
Linear Terpenes 
The most simple terpene is isoprene. The spectral response of isoprene involves a 
large absorbance at 362 nm (Figure lO(A)). The absorptivity is very small at 0.02 M, and 
isoprene is structurally similar to 1,3-pentadiene with conjugated double bonds being 
found on the end of the carbon chain. The difference between isoprene and 1,3-
pentadiene is in the presence of a methyl carbon sidechain from the internal carbon of 
one of the two terminal double bonds rather than off one of the outside double bond 
carbons as with 1,3-pentadiene. The extremely small absorptivity cannot be explained by 
the presence of two terminal double bonds as 1,4-pentadiene also contains two terminal 
double bonds although they are methylene bridged rather than conjugated. The cause of 
the spectral response of this do~ble bond configuration will only be understood when the 
mechanism is better understood. 
Myrcene, squalene and famesol are different from the pentadienes and from each 
other (Figure 9). Myrcene is characterized by a broad maximum at 370 nm with a broad 
shoulder around 454 nm (Figure lO(D)). Squalene has a maximum at 390 nm and a broad 
tail across the longer wavelengths (Figure lO(C)). Finally, famesol has two distinct 
maxima at 384 and 486 nm (Figure lO(B)). 
All of the linear terpenes and the included small-unsaturated compounds have 
unique spectra and should be discriminable in mixtures. It is important to remember that 
the equivalent maximum absorbance observed for the two 1,3 and the 1,4-pentadiene 
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does not preclude spectral determination and isolation of the compounds. The spectra at 
415 nm are different while all three spectra are very similar at 494 nm. This is a good 
indication that the spectra are linearly independent from each other and therefore 
determinable by a variety of multivariate analysis methods. 
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Figure 9. Terpene structures. 
35 
0.8 
0.7 
0.6 
(I) 0.5 0 
C: 
m 
.c 0.4 .... 
0 
U) 
.c 0.3 <( 
0.2 
0.1 
0.0 
350 400 450 500 550 600 650 
Wavelength 
Figure 10. Overlaid spectra of all linear terpenes including A) 10 µl of 
0.25M isoprene, B) farnesol, C) squalene, D) myrcene, E) trans-piperylene, 
F) 1.4-pentadiene. G) cis-piperylene. 
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Cyclic Model Compounds 
The cyclic terpenes are particularly interesting due to the homogeneity in 
structural motifs. For example limonene, carvone, and a-pinene are all very similar 
structurally (Figure 9). The spectral response for a-pinene, limonene and 13-pinene are 
almost exactly the same (Figure 9). All three have a large maximum at 388 nm and 
smaller absorbance at 494 nm (Figure l l(A,B,C)). Limonene and a-pinene are 
structurally similar, as the double bond for both is endocyclic. Limonene has another 
double bond on its sidechain. Because the spectra for the limonene is so close to that of 
a-pinene, the difference of the two spectra would indicate the contribution by limonene's 
external double bond would be inconsequential. 13-pinene is similar to a-pinene except 
the double bond is exocyclic rather than endocyclic. This structural variation would be 
expected to give significantly different spectra in the chromogenic reaction. However, 
the resulting spectrum for 13-pinene is very similar to the response for a-pinene. 
The structural similarity between limonene and carvone is dramatic. The only 
difference is the presence of a ketone forming an unsaturated ketone with the endocyclic 
double bond. The response of carvone is dramatically lower than that of limonene 
(Figure ll(E)). This indicates that the presence of the ketone prevents the production of 
the chromophore associated with limonene. There is some coloration formed, however, it 
is less intense and less sharp than that of limonene. 
The side chain of limonene is analogous to the methyl-substituted double bond 
found in isoprene. It may be that terminal double bonds with a single methyl substitution 
are structurally inappropriate for the chromogenic reaction with AC. 
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Camphene has an exocyclic double bond similar to the double bond of P-pinene. 
The spectral response to camphene is, however, significantly lower than that of P-pinene. 
Camphene is also slightly shifted from 288 nm to 284 nm and has a broadened base at 
longer wavelengths (Figure 1 l(D)). The only differences in the local structures of the two 
compounds are the substitution on the p carbons and the bicyclic structure. 
From the camphene results it seems the reaction only requires a -CH=CH-CH2-
group to occur. The possible combinations of carbons that create this simple structural 
motif are vast. The reaction is highly influenced by the structural environment in the 
analyte. Variations as simple as an added ketone or as subtle as the differences in 
camphene and P-pinene contribute to the spectral uniqueness of practically all of the 
analytes tested. 
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limonene, C) 13-pinene, D) camphene, E) carvone. 
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Polyunsaturated Fatty Acids 
The reaction of saturated fatty acids gives essentially background absorbance. 
Oleic acid has a single unsaturation in the middle of the 18-carbon chain. It was 
previously suspected that single unsaturated acids did not give spectroscopic responses in 
the chromogenic reactions. It was discovered that a small response does occur with AC 
and both zinc acetate and PA catalysts. An aliquot containing 5 X 10-7 moles of oleic 
acid gives a small response. Oleic acid as a monounsaturated chain gives a very small 
absorbance that requires large concentrations to detect (Figure 12(H)). This makes both 
saturated and monounsaturated species physiologically irrelevant. All other fatty acids 
were observed at the same concentration ( except conjugated linoleic) so that 
stoichiometric comparisons can be made. 
Methyl linoleate has a maximum absorbance at 362 nm. The second absorbance 
at 422 nm has a relatively lower absorptivity (Figure 12(G)). The result for the trans 
isomer of methyl linoleate (methyl linolelaidate) indicates a difference in the absorptivity 
at 422 nm while close correlation exists at the 362 nm region (Figure 12(F)). This 
variation at 15 minutes seems to indicate the ability to distinguish between the cis and 
trans linoleic acid isomers in serum (Figure 15(A and B)). Gamma-linolenate and 
linolenate acids also present unique spectra at 0.02 M stock concentration (Figure 12(D 
and E)). Conjugated methyl linoleate (Figure 12(A)) is significantly different in intensity 
from methyl linoleate (Figure 12(G)). It is clear that conjugated methyl linoleate is not 
proportional to methyl linoleate at 15 minutes (Figure 14(inset)). Even greater 
differentiation is found when the kinetics of conjugated methyl linoleate and methyl 
linoleate are compared (Figure 13(Top & Bottom)). The kinetics at 422 nm is 
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significantly more complex for the conjugated methyl linoleate with a decline in the 
spectral intensity after seven minutes at 422 nm. 
The apparent ability to distinguish cis and trans isomers in linoleate and 
linolelaidate has significance in the determination of both physiological and foodstuff 
composition of trans fatty acids. It is currently necessary to do separations for the 
determination of trans fatty acids found. in complex mixtures such as foodstuff or 
biological samples. The potential for a detection method for cis and trans fatty acids 
isomers cannot be overstated. 
The regioisomer differences observed for methyl linolenate and gamma methyl 
linolenate are not easily explained. The unsaturations affect the rigidity of the fatty acid 
chain. It is clear that regioisomers interact with physiological systems in a unique ways 
(see Chapter I). In the living system, such structure dependence is to be expected. The 
kinetics of the reaction could be affected by the change in the flexibility of the fatty acid 
chain depending on the unsaturation location. This phenomenon is of interest and 
warrants further study. 
The kinetic difference between conjugated methyl linoleate and methyl linoleate 
could allow the determination of the two in a mixture. In binary and more complex 
mixtures, quantitative analysis of the kinetics of the reaction may allow quantitation of 
the levels of conjugated methyl linoleate not possible by simple analysis at a standard 
time. It should be noted that the differences between linoleate and methyl linolelaidate 
at 15 minutes are not due to dramatic kinetics differences as with conjugated methyl 
linoleate and methyl linoleate. They are rather do to a small difference in the monotonic 
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progression in the kinetics at 422 nm resulting in a larger absorbance for that wavelength 
at the 15 minute endpoint (Figure 15(including inset)). 
The primary hypothesis for the reagent's selectivity in PUFAs attributes the 
difference in spectral response to the number of unsaturations. The ability of the reagent 
to produce color with fatty acid chains is different from purely acidic reaction such as the 
L-B reaction which itself does not give a response with PUFAs (Figure 16(B-D)). While 
the cholesterol molecule gives a good response (Figure 16(A)). Taking into account the 
current hypothesis for color formation in the case of acid reactions with sterols involve 
the process of dehydrogenation, it is difficult to see how dehydrogenation is a viable 
mechanism for the formation of coloration in lipid chains. The isolated double bounds in 
all of the fatty acids are methylene bridged and for all practical purposes equivalent in 
terms of their potential to be involved in dehydrogenation reactions. This means the 
dehydrogenation to form conjugated chromophores would not be as selective as the 
presented chromogenic reaction. The alternative hypothesis involves a buildup of cyclic 
structures utilizing the fatty acid as a template (see Chapter I). In this mechanism, unique 
energy levels within the electron orbitals of the product associated with the spectral 
absorbances would not be independent of the template. The reaction does not depend on 
the locations of the double bonds but rather the number of methylene bridged double 
bonds in a group. 
The spectral dependence on the number of unsaturations, the regioisomers and 
cis/trans confirmations support the hypothesis of a synthetic mechanism. The one · 
anomaly in this deductive trend is the fact that the PUF As with 5 and 6 unsaturations 
appear to have almost the same spectra at 15 minutes. Eicosapentaenoate and 
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docosahexaenoate are both omega-3 fatty acids with no obvious reason for the similarity 
iri their spectra (Figure 12(B and C)). Methyl linolenate contains three unsaturations in 
the omega-3 positions and forms an independent spectral response. This means the 
omega-3 unsaturation alone does not cause Eicosapentaenoate and docosahexaenoate to 
be similar. 
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Figure 12. Overlaid polyunsaturated fatty acid spectra for 10 µL of 
0.02 M (unless stipulated otherwise) reacted with 1.0 mL acetyl 
chloride catalyzed · by 40 µL of perchloric acid at 15 minutes 
including; A) methyl conjugated linoleate (O.OlM stock) B) methyl 
eicosapentaenoate C) methyl Docosahexaenoate D) gamma-methyl 
linolenate E) methyl linolenate F) methyl linolelaidate G) methyl 
linoleate H) methyl·oleate (2.5 times more concentrated). 
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Figure 13. (TOP)) Electronic absorbance spectra of the reaction of 10 µL 0.01 M 
conjugated methyl linoleate with 1.0 mL acetyl chloride and 40 µL perchloric 
acid over 20 minutes Inset: Kinetic plots of 372 and 422 nm over reaction time. 
(BOTTOM)) Electronic absorbance spectra of the reaction of 10 µL 0.02 M 
methyl linoleate with 1.0 mL acetyl chloride and 40 µL perchloric acid over 20 
minutes Inset: Kinetic plots of 372 and 422 nm over reaction time. 
45 
Q) 
u 
C: 
1.0 
0.8 
i 0.6 
I.. 
0 
U'J 
.c 
<( 0.4 
0.2 
A 
400 
<D0.96 
0 
C io.64 
,._ 
0 
Cl) 
~ 0.32 
-
<C 0.00 
500 
-~ 
0.00 0.25 0.50 
B (absorbance) 
600 700 
Wavelength (nm) 
Figure 14. Overlaid A) 10 µl of 0.01 M conjugated methyl linoleate and 
B) 10 µl of 0.02 M methyl linoleate. Inset cross-correlation plot of the 
absorbance values of conjugated methyl linoleate versus absorbance values 
of methyl linoleate. 
46 
0.6 
0.60 
0.5 
Q) 
0 0.45 C 
co 
0.4 .c ,._ Q) 0 0.30 (J A U) .c C <( m 
.c 0.3 0.15 422 nm .... 
0 
UJ 
.c 0.00 
<( 
0.2 0 5 10 15 20 
Minutes of reaction 
0.1 
0.0 
400 500 600 700 
Wavelength (nm) 
Figure 15. Overlaid spectra of A) linolelaidic acid methyl ester (average of 10 runs) 
10 µl 0.02M in I mL acetyl chloride with 40 µI perchloric acid and B) linoleic acid 
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Summary 
The results presented in Chapter I give strong evidence that proves the selectivity 
of this reaction in the analysis of unsaturated organic compounds. The reactions on 
model compounds indicate the selectivity of the reagent for a variety of analytes. The 15 
minute spectra of 17 from 26 total steroids (including four saturated cholesteryl esters) 
can be resolved as unique to the other spectra. Eight of the twelve terpene compounds 
can be considered unique compared with the other spectra. From the PUF A set of 
compounds, seven of the eight compounds have unique spectra. The reaction can 
distinguish among conformational and location isomers. Compounds with differences as 
small as a single carbon, as in the analysis of 17-alpha-methyl testosterone and 
testosterone, can be determined. 
The results indicate an · alternative reaction mode with the selectivity of species 
that have equivalent unsaturations. The hypothesis before this series of reactions was that 
the reagent only reacted with double bonds. The current results, especially those of the 
steroid compounds, raises questions about the in:(luence the unsaturated and heteroatomic 
structure of an analytes may have on the reaction products and resulting spectra. While 
the mechanism of the reaction has not been elucidated, the understanding about the nature 
of the chromogenic reaction has been increased. Both unsaturated and saturated portions 
of the analyte may contribute to the spectral response of the reaction. This indicates a 
large increase in the selectivity the reagent has with any given analyte. 
The results presen,ted also indicate the additive and quantitative nature of the 
reagent with a variety of· analytes. The compounds considered in Chapter I are 
potentially important analytes in a variety of analytical applications. The determination 
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of molar extinction coefficients was done for all of the physiologically relevant PUF A 
( except methyl oleate ). Linearities for all of those PUF A were good with R squared 
terms above 0.95. Determinations of some of the terpenes indicated limits of detection 
on the order of 1x10·5 M and R squared terms around 0.988. Cholesterol has been 
characterized as linearly related to concentration from the inception of the reagent. Also 
of importance is the additive nature of the compounds as indicated by the difference 
spectra of the unsaturated cholesteryl linoleate and cholesteryl linolenate with methyl 
linoleate and linolenate respectively. This additivity and consequential lack of mutual 
interference between the analytes is a requirement for the utility of the reagent in the 
simultaneous determination of mixtures using multivariate analysis methods. 
The determination of cholesterol and PUF A is directly related to the analysis of 
human sera for the determination of disease states. Current clinical methods utilize the 
determination of cholesterol for the analysis of disease states. The utility of analyzing 
PUF A is not well developed as a separate field in the current literature, however there are 
a variety of diseases that result in, or are caused by, a variation in the PUF A profiles of 
the blood ( see introduction Chapter II). 
The ability to determine conjugated unsaturated species such as conjugated 
methyl linoleate is related to the determination of oxidative intermediates and oxidative 
stress (see introduction Chapter II). If the reagent can be used in the determination of 
oxidative stress levels, the early detection of a number of oxidative stress. related 
diseases, from atherosclerosis to Alzheimer's disease, may be impacted by the 
availability of this reagent. 
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Results from Chapter I indicate the umque nature of the new chromogenic 
reaction presented. When the results of the standard colorimetric cholesterol reaction, the 
L-B reaction, is compared to the new chromogenic assay it becomes apparent that the 
new reaction is different. First, the new reaction creates a larger absorbance with an 
equal amount of cholesterol indicating an increased molar extinction coefficient resulting 
in increased sensitivity for cholesterol. The second difference between the two reactions 
is the inability of the L-B reaction to detect PUFA. This difference may be indicative of 
. a variation in the reaction mechanism. In fact, comparison of the accepted reaction 
mechanisms for L-B with the results with the new reagent further supports the idea of an 
alternative reaction mechanism. The dehydration mechanism is not a viable option for 
compounds such as the unsaturated pentadienes. 
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CHAPTER II 
DETERMINATION OF MIXTURES 
Lipoproteins Introduction 
Lipoproteins are the carriers of the hydrophobic cholesterol and triglycerides 
considered in the routine clinical analysis of serum. They are composed of hydrophobic 
cholesterol esters 'and triglycerides in the interior of the particle. The more hydrophilic 
free cholesterol and phospholipids are on the surface of the particle. Also on the surface 
are apolipoproteins. These charged proteins help make the lipoprotein soluble. They 
also act in the function and interaction of the lipoprotein within the living system.26 
Chylomicrons are large lipoproteins that originate in the gut. Chylomicrons are 
primarily composed of triglycerides (90%). They have four apolipoproteins associated 
with them including a fragment of the apolipoprotein B-100 called apo B-48 as well as 
apo Al, C, and E. They are present in large numbers immediately after meals. They are 
taken up by the liver with the apo E acting in the control mechanism. Chylomicrons are 
cleared within twelve hours of a meal, and are the reason that fasting is incurred prior to 
serum sampling. 26 
Very low-density lipoproteins (VLDL) are large lipoproteins originating from the 
liver. They have apolipoprotein B-100, apo C, and apo E. VLDL is active in the 
transport of triglycerides to the cells of the body. The VLDL loses triglycerides 
metabolically, consequently becoming smaller in diameter. During this process, the 
apolipoprotein C dissociates from the particle. The resulting particle is the intermediate 
density lipoprotein (IDL).26 
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Fifty percent of the IDL that forms from VLDL is taken up by the liver. 
Apolipoprotein E facilitates this uptake. The other 50% lose the apolipoprotein E that 
remained from the VLDL form. Leaving a particle that contains only apolipoprotein B-
l 00 and is high in cholesterol. This new form of IDL is the low-density lipoprotein 
(LDL) particle.26 
LDL particles are taken into cells that need cholesterol through endocytosis. This 
endocytosis is facilitated by the apolipoprotein B-100 (VLDL, IDL, and LDL all have B-
100). Roughly sixty seven percent of the TC in the serum is found in LDL particles.26 
High-density lipoprotein (HDL) particles act in the removal of excess cholesterol 
from the cardiovascular system. This uptake function is unique to the HDL particle. 
HDL is formed in the liver, intestine or circulatory system, and contains 20-30% of the 
total serum cholesterol. The HDL particle contains lecithin-cholesterol acyl transferase 
(LCAT), which acts to esterify free cholesterol. Apolipoprotein A-1 acts in the 
cholesterol esterification in conjunction with LCAT. Apo A-1 is the main apolipoprotein 
in HDL particles. Cholesterol ester transfer protein acts to move esterified cholesterol 
from HDL to IDL or LDL. The cholesteryl ester is cleared via the uptake mechanisms 
for these lipoproteins in the liver. Cholesterol is eliminated from the body in the bile as 
either free cholesterol or bile acids. 26 
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Current Lipoproteins Determinations and Diagnostics 
The measurement of lipids in sera involves the quantification of TC or total 
triglycerides (TG) and the determination of the lipoproteins. Currently there are a variety 
of diagnostic tools for the analysis of lipids and lipoproteins. The current standard 
method is the enzymatic determination of TC, TG and HDL-C followed by the 
Friedewald approximation, which calculates the LDL-C. Prior to the enzymatic method, 
there were chemical methods such as the L-B reaction (see Chapter I) and 
ultracentrifugation analysis (beta quantification or BQ) of the lipoprotein fractions. 
These two techniques eventually became the CDC standard methods BQ and Abell-
Kendall for cholesterol analysis. 
A number of new techniques have become available in the last decade. One of 
the most important is the direct LDL-C concentration determination method. This 
technique involves the selective precipitation of all lipoproteins except LDL and Lp(a). 
The LDL and Lp(a) ate subsequently measured using the cholesterol enzymatic 
determination. Other analytical techniques under development for routine use include 
gradient gel electrophoresis, NMR, and lipoprotein high performance liquid 
chromatography. These alternative methods do not enjoy the acceptance of the 
enzymatic Friedewald approximation due to the lack of substantiating studies. 
As new analytical tools for lipoprotein analysis are developed, new risk factors 
for cardiovascular disease need to be addressed. A number of new risk factors are 
currently in the verification stages. For a risk factor to be considered for routine or semi-
routine analyses it must have substantial prospective and retrospective clinical supporting 
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evidence. The most commonly known new risk factors include trans-fatty acids, 
apolipoprotein a, and homocysteine. Other future risk factors are fibrinogen, 
antioxidants, LDL oxidizability, and the subclasses ofHDL and LDL lipoproteins.26 
Standard Lipoprotein Clinical Methods 
The current standard methods used for the primary screening of patients uses the 
enzymatic analysis of TC and TG combined with the Friedewald equation to approximate 
the LDL-C value. Beyond this initial screening, standard methods for the analysis of 
dyslipidemias include analysis of lipoproteins. If lipoprotein analysis warrants concern, 
the primary screening is followed by more specialized tests such as pheno- and 
genotyping of lipoproteins or quantitative analysis for the presence of chylomicrons in 
fasting serum. Furthennore, direct determination of the LDL-C can be done using 
ultracentrifugation or selective precipitation to help verify the dyslipidemic state. 
Both plasma and serum measurements are used for the analysis of lipids in the 
blood. When collecting plasma samples, EDT A treatment for coagulation prevention is 
preferred to avoid secondary outcomes such as oxidation and bacterial growth. Both 
cholesterol and triglycerides are 3 % greater in serum than in plasma. HDL-C 
concentrations are 5-10 % lower in non-fasting serums. This results in an acceptable 
error on the side of increased risk that is resolvable with further testing.26 Biological 
variances can be significant in the routine determination of serum lipids. The (%) 
biological variances are: TC (6.1), triglycerides (22.6), LDL-C (9.5), and HDL-C (7.4).27 
The patient should be fasting 10-12 hours prior to the blood draw. The patient 
should also have avoided alcohol, and the diet of the patient should be normal and steady 
for 2-3 weeks prior to sampling. In addition, blood work should be avoided during a 
55 
period of 2-3 weeks after minor illness. If the patient has undergone a major illness, 
surgery, or trauma, blood sampling should be avoided for 3 months. The degree of 
physical activity just prior to taking a venous sample is a variable that has to be 
controlled. It is recommended the subject be at rest for five minutes prior to the blood 
draw. Finally, any medication that alters lipid levels should be discontinued, if possible, 
3 weeks before samples are taken. 26 
Enzymatic Methods 
There are a several variations of the enzymatic methods used to determine the 
lipids in serum and plasma. The routine method involves enzymatic reactions that lead to 
products that can then form chromophoric indicators of concentration. An example of 
this type of diagnostic procedure precipitates the LDL and VLDL lipoproteins with an 
appropriate agent such as dextran sulfate or phosphotungstic acid. The HDL .. c that 
remains is modified by hydrolyzes of the cholesterol esters using cholesterol esterase. 
The resulting free cholesterol is converted by cholesterol oxidase to cholest-4-en-3-one 
and free H202. The H202 reacts with precursors, which in turn react with a dye to form 
the colored product from which quantitative absorbance measurements are made. From 
the whole serum, the TC is determined separately by the same enzymatic procedure. For 
TG determination, a separate serum sample is treated with lipase to hydrolyze the ester 
bonds between the fatty acids and the glycerol molecule. The glycerol is reacted with 
glycerol kinase to form glycerol-3-phosphate (GP). GP is then reacted with glycerol-3-
phosphate oxidase to form dihydroxyacetone phosphate and H202. The H202 undergoes a 
· similar reaction as in the determination of cholesterol to give a colorimetric response. 
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Friedewald Equation 
Knowing the TC, HDL-C, and TG concentrations, and from extensive clinical 
studies presuming the VLDL-C is equal to the 0.2TG the LDL-C is determined according 
to the Friedewald's approximation: 
LDL-C = TC - 0.2 TG - HDL-C (1) 
Unfortunately, the Friedewald's approximation results are never accurate. If the 
TG is greater than 200 mg/dL, the calculated value of LDL-C compared with a direct 
measurement is marginal. If the TG is greater than 400 mg/dL, the model fails.28 If the 
patient has Type II dyslipidemia or chylomicrons are present the equation is also 
unreliable.26 The use of the Friedewald approximation also requires fasting, as the TG 
levels are uncertain in the presence of chylomicrons. Even if accurate, TG constraints 
exist. The Friedewald approximation also ignores other potentially significant entities 
such as Lp(a) lipoprotein, which can lead to inaccurate LDL-C values.29 
Beta Quantification 
The CDC standard method for determining lipoprotein fractions is the BQ 
procedure. In this procedure, the serum lipoproteins are separated by ultracentrifugation 
enabling LDL-C to be determined directly. This avoids the problems associated with 
hypertriglyceridemic patients and the Friedewald approximation. The Friedewald 
equation is an attempt to approximate the results of direct LDL determination by the BQ. 
Today direct determination of LDL-C is possible by a variety of isolation methods, 
however the National Cholesterol Education Program (NCEP) still recommends the 
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approximation due to an epidemiological study link that demonstrated the importance of 
LDL-C levels.30 It is anticipated that eventually the BQ and Friedewald approximation 
methods will be supplanted by one or more of the direct LDL-C determination methods. 
Alternative Lipoprotein Determination Methods 
Electrophoresis 
Very early in the study of blood lipids physical separations were used to analyze 
lipoproteins and lipoprotein concentrations. Electrophoresis involves the migration of 
serum lipoprotein components through a separating media utilizing electromotive force. 
Electrophoresis of serum components has been used in the analysis of serum components 
since the beginning of lipoprotein studies. However, the more modem forms of 
electrophoretic methods have increased their usefulness in lipoprotein analysis. Various 
separation media can be used for electrophoresis in the analysis of lipoproteins. Common 
separation media are non-denaturing polyacrylamide and agarose gels. Agarose gel 
electrophoresis can be used for accurate lipoprotein determinations.31 Specialized 
separation media are also used. Immuno-electrophoresis allows selective separation 
based on specific interaction with the apolipoproteins present and has the potential for 
direct measurement of apolipoproteins and assays that are more specific.32• 33 For 
instance, a modified electrophoresis method allows the determination of glycated 
lipoproteins as a means for detection of diabetes. 34 
Electrophoresis can be used to directly determine the level of cholesterol of all 
lipoprotein fractions in sera. 35• 36 Electrophoresis can consequently be used to describe 
and identify dyslipidemias.37 Furthermore, it can be used for the determination of 
58 
lipoprotein remnants;38• 39 When electrophoresis of the lipoproteins is done a number of 
disorders can be elucidated. This is particularly useful for patients with borderline 
cholesterol levels. If the beta band in the electropherogram is broad it is an indication of 
Type III dyslipidemia, when a combined hyperlipoproteinemia exists. If the beta and 
pre-beta bands are resolvable, a patient has Type II-B dyslipidemia, when both 
cholesterol and triglycerides are at high concentration.26 If the patient has Type III 
dyslipidemia the electropherogram can also indicate beta-VLDL, an altered VLDL 
particle. This is done by first separating the VLDL particles from the other lipoproteins 
by ultracentrifugation and separating them by electrophoresis. If the VLDL shows beta 
mobility instead of alpha-2 mobility, they are beta-VLDL. In electrophoresis, any 
chylomicrons present do not migrate. This fact can also be used to determine 
chylomicron presence.26 
Electrophoresis can also give an indication of the charge of the lipoproteins. This 
is important since the oxidized LDL particles are linked to atherogenesis.40• 41 The 
oxidized LDL's surface becomes more electronegative which is detected by increased 
electrophoretic mobility on the electrophoresis gel.42• 43 These oxidized LDL particles are 
termed "LDL-" and they are minimally oxidized with the majority of reactive oxidized 
species being on the surface of the particle.44 Electrophoresis, therefore, can be used to 
assess the level of oxidative stress in a biological system.45 
Electrophoresis also gives information about lipoprotein particle size. There are 
variations in LDL size, which are associated with increased risk for atherogenesis.46• 47 
HDL particle size is indicative of the development stage of the lipoprotein and its 
associated action in cholesterol transport.48 Electrophoretic methods can determine the 
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standard subclasses of lipoproteins such as LDL, HDL, VLDL cholesterol without need 
for precipitation and in an automatable fashion.49' 50 LDL and HDL subclass deviations 
are better indicators of CAD than lipoprotein cholesterol levels and this is detectable with 
electrophoresis almost exclusively.51•53 LDL subclasses may indicate acute risk of 
myocardial infarction. 54 
Electrophoresis has many other potential benefits in analysis. For example, 
standard equipment can be used for the analysis of fatty acids by electrophoresis.55 The 
utilization of efficient capillary electrophoresis for the determination of lipoproteins is a 
developing separation method. 56' 57 Capillary electrophoresis is beneficial in its high 
throughput potential. Capillary electrophoresis is currently readily automatable and 
commercially available platforms are available for this type of electrophoresis. 
Direct LDL-C Determination 
Several direct LDL-C analysis methods currently exist. These methods will allow 
the analysis of true LDL-C for any patient independent of any dyslipidemic state that may 
exist. These methods primarily rely on selective precipitation. A number of separation 
methods have the potential to replace ultracentrifugation including HPLC gel filtration 
and gradient electrophoresis. Selective precipitations are typically based either on charge 
neutralization or on antibody binding.38• 58 
The N-geneous™ LDL-C assay is an example of a direct LDL-C system. It 
utilizes detergents to selectively solubilize LDL away from the other lipoprotein 
components. Results have been shown to be very similar to ultracentrifugation59 and it is 
not affected by glycemic control. The N-geneous™ system is fully automated and is less 
60 
expensive than ultracentrifugation.60 Direct LDL-C determination methods can be done 
on people with dyslipidemias, diabetes and are non-fasting with little error.61-64 
The original studies of cardiovascular risk factors indicated that cholesterol was 
an independent risk factor. The TC value is enough in cases where the cholesterol 
concentrations are significantly high or low. A large segment of the patients undergoing 
cardiovascular screening are borderline patients where TC is misleading in terms of their 
risk of coronary artery disease (CAD). It is in the intermediate values that the cholesterol 
lipoprotein distribution is useful in determining the risk for CAD.65 
If cholesterol is not a suitable risk factor to predict CAD, the lipoproteins are the 
better predictive risk factors.65 Specifically, high VLDL-C and LDL-C are both positive 
risk factors for CAD. High HDL-C concentrations act in a preventive mechanism for 
CAD.66• 67 IDL particles are also associated with an increased risk of atherosclerosis68 It 
is currently recommended to determine VLDL-C, LDL-C, and HDL-C concentrations 
before making a diagnosis or prescribing a therapy for the prevention of CAD.65 The 
routine determination methods for HDL-C and LDL-C are more time consuming than the 
determination of TC or TG due to separation steps. 69 
While the lipoprotein fractions are better for borderline patients, for a small 
number of patients the values for lipoproteins are also not enough to characterize their 
risk for developing CAD. The subclasses of the lipoproteins are still better as predictive 
indicators. Lipoprotein subclasses have been characterized in terms of their role in 
atherogenesis.70 The LDL particle contribution to atherogenesis largely depends on the 
"particle size" .54• 11•15 The small LDL particles infer a higher risk of CAD at normal LDL-
C concentrations. 65 The associated beneficial effect of HDL does not occur across all of 
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the HDL subclasses. While the largest HDL particles are protective against 
atherosclerosis, the two smallest particles are positive risk factors for CAD.76• 77 The 
inability of the body to clear chylomicrons is associated with increased risk for coronary 
heart disease (CHD). The inability to clear chylomicrons causes the presence of larger 
VLDL lipoprotein particles to appear in fasting serums that correlates with an increased 
risk of CAD.78' 79 The lipoprotein subclass profile can demonstrate increased risk for 
patients with HDL-C and LDL-C values that are considered "normal" by the NCEP 
definitions.80 The lipoprotein subclasses are very similar to each other. This results in a 
10 time increase in difficulty to speciate them compared to the standard lipoprotein 
separations. 81 
The determination of VLDL subclasses is not a routine matter and the 
relationships between the VLDL subclasses and CAD are not well studied. Lipoprotein 
subclasses can be determined by chemical precipitation, ultracentrifugation, 
electrophoresis, and chromatography. The analysis of the lipoprotein subfractions 
requires either a separation or a marker specific for each of the subclasses.65 
NMR Analysis 
NMR can determine the size of lipoprotein particles based on the relative nuclear 
magnetic resonance shifts.65 The NMR procedure utilizes the absorbance shift in the 
methyl group resonance for each different particle size. These different resonances are 
due to the oriented phospholipids on the surface of the lipoprotein.82 
One limiting factor of NMR is that the particles are only determined by size and 
therefore any overlap in the size of the particles, whether of the same or different 
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lipoprotein classes, are viewed as equivalent. In addition, any interesting chemical 
variation is lost in NMR analysis. This can be important, for example, because 
"chylomicron remnants" and VLDL particles are of a similar size. In addition, the 
apolipoprotein is not distinguished so important variants like Lp(a) derived from LDL are 
not represented in the data. 65 
Because the NMR method only determines the particles based on their size, errors 
occur when translating the NMR data to cholesterol concentrations found in the various 
lipoproteins. The values determined by the standard methods for LDL-C and HDL-C 
ignore the variation of the concentration of cholesterol in the particles, 83 i.e. only 
cholesterol in the lipoprotein fraction is determined. The number of LDL particles is 
determined assuming the LDL particle contains a standard amount of cholesterol. In the 
case of NMR this source of error in LDL particle number determination is avoided. The 
actual cholesterol concentrations of LDL and LDL subclasses are determined by analysis 
of a "bulk lipid signal" from NMR analysis which does not vary based on the transfer of 
cholesterol from the core of the particle. Therefore, traditional data for the association of 
lipoproteins to diseases are· based on the cholesterol found in the particle. The actual 
number of lipoproteins is not the standard risk factor. Further, the determination of 
cholesterol from the total number of lipoproteins is complicated by the same variation of 
cholesterol that makes the NMR analysis more rigorous.65 
While the NMR method is limited in a number of important ways, the method 
does have a few advantages. For example, chylomicrons can be determined with NMR 
so having a fasting sample is not necessarily needed.65 NMR also has the potential to do 
direct determination of conjugated fatty acids in a mixture with pure fatty acids.84 The 
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ability of NMR to determine species with specific resonances may prove extremely 
powerful in the analysis of chemical components of blood. Another limiting factor is that 
the analysis is based on methyl resonances only and is not specific and readily susceptible 
to interferences. 65 
Why Lipoproteins are the Current Model for Diseases 
Introduction to Dyslipidemias 
There are varieties of classification systems for lipid disorders. One system is the 
Fredrickson classification. 85• 86 Dyslipidemias can be simply classified as 
hypercholesterolemia, hypertriglyceridemia, high LDL-C, low HDL-C, or some 
combination of the above. This simplified system ignores the fact that the dyslipidemia 
can be primary (genetic) or secondary (non-genetic).26 Some secondary causes of 
hypertriglyceridemia are obesity, pregnancy, and diabetes mellitus. Some secondary 
causes of hypercholesterolemia are hypothyroidism, nephrotic syndrome, and 
cholestasis. 26 
Primary causes of hypercholesterolemia include a single gene mutation in LDL 
receptors.87 If this disorder is homozygote the TC levels can rocket to 600-1000 mg/dL. 
In the heterozygote form TC levels are much lower (300-450 mg/dL). The heterozygote 
form of the disorder involves a one-half decrease in LDL receptor function.26 The 
homozygote form of this disorder can be devastating to the patient who suffers from 
tendon xanthoma and has atherosclerosis before midlife.26 The mutations that cause this 
disorder are well understood. 87• 
64 
Hypertriglyceridemia, when taken independently, is a risk factor for CAD. 
However, when TG concentrations are incorporated with other risk factors its 
performance as a risk factor falls below acceptable limits.85' 86 Complex algorithms have 
been developed to explain the loss of relevance in TG concentration when combined with 
other factors. 88 A primary (genetic) cause of hypertriglyceridemia is Type IV 
dyslipidemia. Type IV dyslipidemia is autosomal dominant and results in overproduction 
of triglycerides in the liver. A characteristic of this dyslipidemia is the presence of larger 
VLDL particles due to the extra triglycerides available at the liver. There are no 
biochemical markers for this disorder and there is no evidence to link this disorder to 
increased risk of CAD. The serum TG levels tend to be less than 600 mg/dL and the 
LDL-C concentrations tend to be within the normal range.26 Combined these symptoms 
make it difficult to diagnose the condition given no specific marker. 
TG levels above 1000 mg/dL are associated with chylomicronemia syndrome. 
Such high levels of TG mean the patient could have pancreatitis.26 Chylomicronemia can 
be caused by lowered function of lipoprotein lipase (LPL).89 This lowered level of 
enzyme function may be due to lower levels caused by an autosomal recessive disorder, 
or by lowered level of apolipoprotein C-II that is necessary for LPL to function. LPL 
deficiency shows up in childhood, and is not linked to early atherosclerosis. Low levels 
of apolipoprotein C-II is a rare disorder caused by an autosomal recessive gene.89 
Another cause of chylomicronemia is Type V dyslipidemia. This is especially 
relevant to the adult onset of chylomicronemia.26 These cases require the presence of 
familial hypertriglyceridemia. To this existing disorder some secondary cause (obesity, 
alcohol, etc) facilitates the chylomicronemia onset. Type V disorder is marked by high 
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VLDL-C concentrations and the presence of chylomicrons in fasting serums. Type Vis 
genetic in its nature but the details of how it is inherited are not clear.26 
Combined dyslipidemias occur when both TC and TG levels are above normal. 
There are two main subcategories of combined dyslipidemia. The first is combined 
familial hyperlipidemia (CFH); the most common form of combined dyslipidemia.85• 86• 90, 
91 CFH is also called "familial multiple lipoprotein-type hyperlipidemia". This disorder 
can cause increased concentrations of cholesterol, triglycerides, or both. CFH is 
autosomal dominant, and causes overproduction of apolipoprotein B-100. Consequently, 
increased levels of apolipoprotein B-100 are found in VLDL, IDL, and LDL lipoproteins. 
Patients with CFH have increased risk of atherosclerosis. The diagnosis of this disorder 
relies on the presence of low HDL-C concentrations and elevated apolipoprotein B-100 
levels in the serum.26 A similar disorder to CFH is hyperapobetalipoproteinemia where 
there are normal levels of LDL-C and increased levels of apolipoprotein B-100. This 
disorder is associated with increased risk for CAD.92 
The second main subcategory of combined dyslipidemias is Type III disorder, 
also called dysbetalipoproteinemia. In this disorder, the patient is homozygous for the 
apolipoprotein E-2 gene rather than the normal apolipoprotein E-3. This difference in 
alleles does not directly cause Type III disorder. One percent of the population is 
homozygous for apolipoprotein E-2. It requires secondary causes to lead to the onset of 
Type III disorder. Secondary causes such as obesity or diabetes can lead to the onset of 
Type III disorder. Apolipoprotein A-2 is not as good at inducing uptake at the liver as 
the other forms of apolipoproteins E. This results in decreased chylomicron and IDL 
particle uptake by the liver and their subsequent increased concentration in the circulatory 
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system.26 Unique to Type III disorder is the presence of a "broad beta band:" in the 
electropherogram of the lipoproteins. Due to the high concentration of chylomicrons the 
analysis of this sample requires direct determination of VLDL-C or LDL-C given the TG 
concentrations are beyond the working range of the Friedewald approximation. A 
confirming measure is if the VLDL-C versus TG ratio is greater or equal to 0.30. Type 
III patients will experience increased atherosclerosis.93 
In hyperapobetalipoproteinemia, the LDL lipoprotein tends to be the smaller, 
denser version. These smaller LDL particles are found with many disorders including 
hypertriglyceridemia, insulin resistance, glucose intolerance, and hypertension. This 
presence of small dense LDL particles in so many disorders may indicate a pathological 
relationship between these special LDL lipoproteins and the disorders. The prevalence of 
this phenomenon has lead to it being called syndrome X by researchers.94 
The interest in the relationship between serum lipids and their relationship to 
disease is divided into two fields of study. The first is the study of lipoprotein 
composition and the second is the study of actual fatty acid composition. 
Lipoproteinology is currently the model used as a marker for a number of diseases 
including atherosclerosis, CHO, and susceptibility to stroke. The current standards for 
lipoprotein cholesterol were reiterated in a report published in 2002 by the NCEP. In the 
report the standards for lipoprotein cholesterol and serum total values of LDL-C less than 
100 mg/dL; TG less than 150 mg/dL; and HDL-C is greater than 40 mg/dL are 
recommended as the normal range.28 
The NCEP has issued three Adult Treatment Panels (ATP) since it's inception in 
1983. The variation of the standard values is of interest. In the ATPIII (2002) the value 
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for TG is lower than the value espoused in the ATPII (1993) of 200 mg/dL. ATPII had 
already lowered the TG value from 400 mg/dL recommended in ATPI (1983). These 
variations indicate the continued development of the models underlying these values.28 
The need for variation in the cutoff values is made clear by the fact that in 1999 thirty 
three percent of the patients with CHO had "normal" LDL-C values defined in the 
ATPll.95 The ATPU report recommended alternative LDL-C determination if the 
cholesterol level is normal (<200 mg/dL) but the HDL-C is less than 35 mg/dL; TC is 
borderline (200-239 mg/dL) and two or more risk factors are present; if TC is greater or 
equal to 240 mg/dL.26 
There are many risk factors associated with CAD. One of the risk factors is age. 
There is an increased risk for CAD in men 45 years and older, and for women 55 years 
and older. Women with premature menopause without estrogen replacement therapy are 
considered at greater risk before 55 years-of-age. Another risk factor is a family history 
of CAD. Smoking is one of the most controllable risk factors. Hypertension and 
diabetes mellitus are diseases that increase the risk of CAD. IfHDL-C is greater or equal 
to 60 mg/dL this counts as a negative risk factor, i.e. HDL-C is greater or equal to 60 
mg/dL helps protect against CAD.26 
The risk factors currently used may be supplanted or supported by a number of 
risk factors now being evaluated. These include apolipoprotein concentrations in the 
blood. For example, higher apolipoprotein B and lower apolipoprotein A-1 
concentrations, resulting in a low apo A-1 I apo B ratio, is a marker for CAD. 
Prospective studies are still necessary for this measure to be accepted as a routine 
evaluation method.33• 96 Standardization in measuring apolipoproteins is not complete but 
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in general, progress is being made. The accurate measurement of apolipoprotein B-100 
and apolipoprotein A-1 will be a method in the future. 97 Apolipoprotein B-100 
measurement will help diagnose hyperapobetalipoproteinemia that results in 
atherosclerosis in patients with normal LDL-C concentrations.26 Apolipoprotein(a) 
(Apo(a)) is an important apolipoprotein98-101 found in lipoprotein(a) (Lp(a)). Lp(a) is 
similar to LDL in lipid composition and apolipoproteins except the addition of Apo(a). 
Apo(a) is a glycosylated lipoprotein that exists with disulfide bonds linking it to the 
apolipoprotein B-100 in the surface layer.26 Apo(a) has high amino acid sequence 
identity with plasminogen. This fact may prove important for determination of the origin 
of Apo(a). Apo(a) levels are not readily influenced by external factors. It seems to be 
under genetic control. 26 
A large number of studies, involving various designs, have shown correlation 
between LDL-C and atherosclerosis. Some of these studies have shown the effectiveness 
of treatments that lower LDL-C on CAD.102, 103 
The Framingham study showed that low HDL-C is a risk factor for CAD.66 
Lowered HDL-C can result from secondary factors including smoking, diabetes, and 
obesity. A primary (genetic) cause of lowered HDL-C is hypoalphalipoproteinemia.26 
Exceptions to the trend of low HDL-C as beneficial do exist. Individuals with 
apolipoprotein A-1 mutation have lowered HDL-C concentrations but no increased risk 
of atherosclerosis.88 Hyperalphalipoproteinemia produces HDL-C levels greater than 70 
mg/dL. These individuals seem to be at lower risk for CAD.26 
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Alternatives to Lipoprotein Analysis 
Total Lipids Determination and Human Diagnostics 
The lipid profile of the serum has been investigated in a variety of studies 
utilizing a variety of analytical methods. The most common methods are 
chromatographic methods: high performance liquid chromatography (HPLC), gas 
chromatography (GC), and thin layer chromatography (TLC). The results of these 
studies are largely dependent on the hypothesis being tested. Overall, these studies give 
an indication of the importance of the serum fatty acid composition in relation to disease 
states. 
How Do Unsaturations and Cholesterol Affect Health 
PUF As are known to affect the lipid composition of the serum. Fish oil, high in 
PUF As, lowers levels of VLDL and IDL lipoproteins when taken at I g/day.104 Fish oil 
has also been used successfully in the treatment of type IV, V, combined and 
chylomicronemia dyslipidemias. 105•106 Fish oil can counter the results of 
hypertriglyceridemia that is associated with carbohydrate intake. 107 In the liver of 
"hyperlipidemic rats" docosahexaenoic fatty acid (DHA) prevents the excessive 
production of lipids. 108 
Omega-3 fatty acids are essential dietary components related to cancer 
development and treatment. Cancer is related to diet 20-60% of the time, depending on 
the type of cancer.109 Prospective studies have suggested fish supplementation can be 
protective for women against colorectal cancer.110 When challenged with carcinogens, 
eicosapentaenoic acid (EPA) and DHA inhibit carcinogenesis in the colon of rats.111 Fish 
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oil gave similar results in carcinogen challenged rat models. 112 HT29 human cancer cells 
in the nude mouse colon also responded with in a positive way to fish oil treatment. 113 
Liver cancer rat models had positive effects for n-3 PUFA and n-6 PUFA on adenoma 
but not carcinoma. In this study, the PUFA source was plant based and therefore did not 
contain EPA or DHA.114 A study has shown positive effects when hepatic carcinomas are 
treated with EPA and DHA ethyl esters. 115 
The mechanism of action for EPA is that it prevents cell proliferation, and DHA 
acts to stimulate apoptosis. 116 The effect of n-3 PUF A on breast cancer is less clear. 
Animal models showed that EPA and DHA decreased the chance of breast cancer but 
they did not prevent cancer proliferation. 117 A review of data from 1966 to 1994 indicates 
that n-6 PUF A and saturated fatty acids are associated with increased growth of breast 
cancer, while n-3 PUFA are slightly inhibitory.118 Overall, the lack of congruence 
between the studies is likely due to confounding factors not considered in all studies. 116 
n-3 PUF A does prevent metastasis of breast cancer. 119•121 EPA prevented cancer growth 
and metastasis in rat breast cancer models. 119 Breast cancer growth and lung metastasis is 
prevented with menhaden fish oil supplementation.120 Using transplanted tumor models 
the protective effect on n-3 fatty acids are seen with inhibition of breast cancer 
proliferation and metastasis. 121 EPA treatment inhibits the metastasis of liver cancer. 122 
However, fish oil treatment resulted in promotion of metastasis in comparison to a 
safflower diet. 123 
In mouse models lung cancer also has increased metastasis with n-3 PUFA 
supplementation compared with n-6 PUF A or saturated oil diet. 124 In mouse models of 
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highly metastatic cancer cells EPA and DHA supplementation resulted in lower lung 
metastasis when compared to linoleic and arachidonic acids. 125 
The beneficial effect of PUF A is associated with increased PUF A peroxidation. 126 
The ability of fish oil to prevent mouse carried breast cancer is limited by vitamin E. 127 
Vitamin E supplementation increased the likelihood of cancer and the proliferation of the 
carcinoma. 128 In a study seeking to increase lipid peroxidation and evaluate its effect on 
human breast cancer cells in mouse hosts, the increase of peroxidation by added iron and 
a peroxidation inducing drug limited cancer cell growth proportionally.129 The 
cytotoxicity of PUF A oxidative products is a significant factor. Hydroperoxides of 
unsaturated fatty acids are cytotoxic. The ability of DHA to affect cancer cells depends 
on the cells ability to counter oxidation processes. The "hydroperoxy-DHA" species is a 
major cytotoxic byproduct ofDHA peroxidation.130 Sarcoma cells were treated with "n-3 
PUFA (DHA>ALA>EPA)" and the n-3 PUFA acted to inhibit cell growth. Vitamin E 
inhibited the toxic effect of these fatty acids while lipid peroxidation was increased with 
all of the fatty acids in the study.131 Most leukemia cells are affected by arachidonic acid, 
EPA, and DHA. The leukemia cells die by both necrosis and apoptosis. EPA causes 
necrosis rather than apoptosis. The effect of EPA is counteracted by the presence of 
vitamin E. 132 
Malignant pancreas cells are induced to undergo apoptosis by EPA, DHA and n-6 
arachidonic acid in vitro. In these cases apoptosis depended on lipid oxidation. 133 
Mitomycin C is an anticancer drug that causes increased oxidation in vivo. EPA has 
been shown to increase the effectiveness of mitomycin C. The increased unsaturated fatty 
acids in the tumor allowed for higher toxicity in the tumor cell. 134• Dietary intake of "pro-
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oxidants" facilitated the effectiveness of anthracyclins against breast cancer. Addition of 
dietary vitamin E inhibited this effect. 135 The use of DHA and EPA also allow the relief 
of cardiotoxic effects of anthracyclins in rat models.136 The amount of n-3 PUF A in 
breast adipose is directly correlated to chemotherapy response. The level of DHA was 
high in patients who responded well to chemotherapy and low in people who did not 
respond well to chemotherapy.137 Anthracyclin effectiveness increased with increased 
levels of DHA. Lipid peroxides and lipid peroxidation products are therefore associated 
with the mechanism of drug effectiveness and the use of these factors can assist in future 
chemotherapy treatment schemes. 138 The use of pro~oxidants combined with fish oil 
· supplementation effectively slowed breast cancer cells in mice. 129 
The increased effectiveness of chemotherapy with n-3 PUF A may not be 
universally due to peroxidation. Cyclophosphamide has enhanced in vivo performance 
with menhaden oil due to the effect of the PUF A in modulating liver detoxifying enzyme 
function and altering liver and carcinoma enzymes that activate cyclophosphamide. 139 
The presence of PUF A in cancer cells also assist in the toxic effects of radiation 
treatment.140 Treatment of rat hosted cancer cells as treated by hyperthermia is enhanced 
with addition of ALA and GLA. 141 In the radiation treatment of cancerous astrocytoma 
cells n-6 GLA and n-3 EPA and DHA all increase tumor toxicity especially GLA. 142 
GLA is toxic only to ''neoplastic astrocytoma cells" not normal astrocytes making it a 
good candidate for cotreatment of these cancer cells with radiation therapy. 143 
EPA and DHA are taken into membranes of rat cells without making them more 
susceptible to peroxidation. 144 n-3 PUF A is taken into several parts of rat liver cells 
rapidly.145 The "physiological conditions" in which the PUF A exists is important since 
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antioxidants can act as prooxidants depending on the partial pressure of oxygen. 146 The 
levels of n-3 PUF A can be manipulated with diet to give optimum n-3/n-6 PUF A ratios 
within a few months. This effect can have benefits for several types of cancer especially 
breast cancer. 147 It is vital that n-3 PUF A effect be considered in terms of n-6 PUF A and 
antioxidant components. The toxicity of PUFA is ·higher for cancer cells than normal 
cells. This is probably due to the lower levels of antioxidants during "malignant 
transformations" .116 
Lipid Oxidation 
Lipids undergo oxidation in the mitochondria in order to be used as energy 
sources. Lipoxygenases are the enzymes that induce hydrogen removal and dioxygen 
reaction in a regiospecific manner. The reaction is very similar to lipid autoxidation 
except it is directed to a specific area of the lipid. 148 
Autoxidation 
Unsaturated lipids can undergo autoxidation through peroxidation. The process 
involves the introduction of both oxygen atoms of diatomic oxygen onto the carbon chain 
of the lipid in a free radical mechanism. 149 Reactive oxygen species (ROS) can induce a 
carbon radical in the chain by heterolytically removing hydrogen from the carbon. 
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The initial reaction is important because the initiation rate strongly influences the 
reaction products. 1s0 Normally unsaturations in lipids are methylene-bridged. However, 
when the free radical is formed in the initiation of lipid peroxidation the double bonds 
rearrange to eliminate the methylene group to become conjugated. The free radicals react 
with dioxygen forming peroxide radicals. 149 
-CH2CH=CHCH=CH°CH- + 02 --+ ••• CH=CHCHoo· (3) 
The peroxide radical can abstract hydrogen form another carbon chain. The 
nature of these free radical reactions dictates that large numbers of "initiations" can be 
achieved by this regeneration of initiator. If the chain has more than one methylene 
carbon between the double bonds, they will not rearrange into conjugation. 149 Peroxides 
tend to form on the outside methylene at the two ends of the unsaturated regions. They 
are less likely to form between double bonds on the methylene bridge carbon.1s1 
Transition metals can catalyze the formation of alkylperoxy radicals or alkoxy 
radicals from existing lipid peroxides. The alkoxy radical can further react to form 
aldehyde, ketone, and hydroxy containing products. Alkoxy radicals can also breakdown 
through chain cleavage producing "short chain aldehydes". 149 Linoleate autoxidation can 
form compounds that are unsaturated aldehydes, such as hept-2-enal, oct-2-enal, and 
deca-2,4-enal. Linolenate autoxidation can form products such as deca-2,4,7-trienal, 
hepta-2,4-dienal, prop-2-enal, and pent-2-enal.1s2 The unsaturated ketone is ubiquitous in 
peroxidation breakdown. Malondialdehyde (MDA) is an autoxidation product commonly 
considered in analytical techniques for oxidation. MDA is produced from a lipid that is 
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at least triunsaturated. The rearrangement of the middle unsaturation to conjugation with 
either of the other double bonds is followed by peroxide formation between the double 
bonds. The peroxide is located closest to the conjugated double bonds leaving a 
methylene group between the peroxy-carbon and the third unsaturation. In this position, 
the peroxy radical can form a peroxy bridge with the third unsaturation. This peroxy 
bridge decomposes into two ketones with the concomitant scission of the bonds beyond 
the alpha carbons to each ketone. Determination of the extent of oxidative degradation is 
achieved by monitoring the products of the autoxidation reactions. MDA is a common 
analyte. As with all free radical reactions the end of the reaction comes with a 
termination step. This involves the reaction of the reactive species on carbon chains with 
other free radicals to terminate both reactive species. The overall result is lipid cross-
linking through carbon-carbon bonds and peroxides.149 
Aldehydes can form protein adducts via protein free radical oxidation or Michael 
Addition of conjugated aldehydes with protein thiol groups. The thiol attacks the carbon 
of the double bond forming an enol that tautomerizes into an unsaturated aldehyde. These 
reactions result in unnatural proteins with lowered or lost functionality, making 
unsaturated aldehyde adducts toxic to cells. The cytoplasmic concentration of total 
"carbonyls" has been estimated as a means of detecting lipid oxidation. Lipid 
peroxidation products are hydrophobic. There is, therefore, an increased level of them in 
the cell membranes. DNA adducts can also be formed with aldehydes such as hex-2-enal 
and malonyldialdehyde.149 This leads to abnormal DNA processing and mutagenesis. 
In lipid peroxidation reactions of serum samples, linoleic acid is the predominant 
fatty acid and therefore is the predominant form of oxidized fatty acid in the serum. 
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Analysis of the oxidation of LDL has demonstrated the importance of the oxidized form 
of linoleic acid in oxLDL formation. 153 
Current Determination of Lipid Autoxidation and Oxidative Stress 
Currently, the methods for the determination of lipid peroxidation in foodstuffs 
and medical applications are well developed, and include chemical, immunochemical, 
and separation methods for the determination of the extent of oxidation of lipids in given 
situations. UV Nisible, fluorescence and chemiluminescence are all used for analysis of 
autoxidation products. 149 Headspace GC is also a commonly used technique. 154• 
A variety of methods are used and preferred in the determination of autoxidation 
of foodstuffs. Peroxide value, hexanal and MDA concentrations are among the most 
common.155 Thiobarbituric acid reactive species (TBARS), lipid peroxide, fluorescence 
and volatiles (including hexanal) are also used. 149 Monitoring the consumption of oxygen 
is useful for foodstuff but is of little use for autoxidation determinations in vivo. 156 
Physiological determinations of TBARS is currently the most commonly used method. 149 
As was described earlier, the formation of free radical sites in unsaturated lipids 
leads to conjugated double bonds. These double bonds absorb light in the UV region at 
234 nm. Detection at 234 nm can be used to determine conjugated dienes in a variety of 
samples. Interference by biological compounds that also absorb in the 234 nm region has 
seriously limited the use of UV detection. Extraction methods have been used to alleviate 
this problem.149 With the advent of second derivative spectroscopic techniques the 
elimination of the extraction procedures is possible. Methylene bridged dienes absorb at 
210 nm, trans-trans conjugated dienes absorb at 234 nm, cis-trans conjugated dienes 
absorb at 244 nm and ketone dienes absorb at 280 nm. 156 
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Determination of peroxides is another procedure commonly used for the 
determination of oxidation. In foodstuffs the procedure involves the dissolution of the 
sample into a chloroform I acetic acid mixture. This solution is reacted with potassium 
iodide. The peroxide acts to form iodine that is reduced with a suitable agent by titration 
to form iodide. This redox titration is monitored with starch as the indicator. 149 The 
endpoint of the titration occurs when the dark blue starch complex disappears. The 
iodine determination can also be monitored with spectrophotometric methods. 157 
Enzymatic detection of peroxides with horseradish peroxidase type II is also possible. 158 
Peroxides can also be determined with chemiluminescence. 159-161 In one study the link 
between toxicity of the cancer drug doxorubicin and lipid peroxidation was determined 
using a chemiluminescent method. 162 Chemiluminescence methods use luminol in 
reaction with hydroperoxides. 149 Fluorescence is achieved using fluorescent indicators 
like Diphenyl-l-pyrenylphosphine.33• 163 
A major class of lipid peroxidation products is carbonyl compounds. Reviews 
have been written on aldehyde containing products. 164 Determination of carbonyl 
containing compounds is commonly done by derivatizing the carbonyl with 2,4-
dinitrophenylhydrazine to form 2,4-dinitrophenylhydrazones. These 2,4-
dinitrophenylhydrazones are detected with UV Nis spectrophotometry.149 This system 
has been used in spectrophotometric detection in HPLC separations of 2,4-
dinitrophenylhydrazone aldehyde derivatives. 165 Currently an immunochemical method is 
being used to detect carbonyl species where the antibody binds directly to the 2,4-
dinitrophenylhydrazones. This allows the detection of the carbonyl species within the 
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context of a living cell. 166 Fluorescence determinations are achieved by forming 
decahydroacridine derivatives164• 167 or by other derivatizations.168 
MDA concentrations can be determined but they are not indicative of lipid 
peroxidation levels in vivo. 164 A very small amount of MDA can be produced from the 
diunsaturated linoleic acid.149 MDA is not the most common peroxidation product. 
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Summary 
This review summarizes current routine clinical methods. It presents the 
importance placed on lipoprotein determination, and emphasizes the current and 
developing methods for lipoprotein isolation and quantification. It reviews why 
determinations of TC and lipoprotein fractions have been traditionally used for the 
determination of lipids in the sera. The association of these values to a variety of lipids 
disease states ( dyslipidemias) is also discussed. 
. The methods of lipoprotein analysis are largely dependent on such techniques as 
centrifugation, electrophoresis, or selective precipitations. These isolation methods have 
made the analysis of lipoproteins accessible for the last few decades. The utility of 
lipoprotein data has been demonstrated in cross-sectional clinical studies to predict risk of 
CAD. Methods under development, including direct determinations of LDL-C, are 
dependent on similar clinical studies to prove the reliability of the method for the 
determination of risk. In fact, every new method, including the one presented in this 
work, requires such clinical verification. 
Methods to separate and analyze individual lipid components have been available 
for several decades. Lipid components in this sense means cholesterol, its esters, 
polyunsaturated fatty acids in a transesterified state, etc. The analysis of these lipid 
species is a tool currently used for the analysis of diseases with associated variations of 
blood lipids. These analyses have depended primarily on isolation of the species by 
separation methods. The use of lipid profiles for the prediction, determination or 
monitoring of disease states is not currently an organized field of scientific study. 
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That the direct determination of lipids by means of the chemical assay described 
in this work can be used for the determination of disease states is supported by the 
literature. The ability of the present method to simultaneously determine the lipid 
components of sera is unprecedented. The assay can determine mono- and 
polyunsaturated fatty acid compositions as well as having a superior detection limit over 
the L-B reaction for the determination of TC. Cholesterol is still considered the 
overriding determinant of cardiovascular risk. High TC is predictive of risk for CAD 
regardless of the lipoproteins concentrations. Combined with the ability to determine 
levels of the PUF A, which are known to be associated with variations of lipoprotein 
ratios and subsequently cardiovascular risk, the chromogenic assay has the possiblity to 
revolutionize routine clinical analyses. 
Beyond the known analytes of cholesterol and PUF A, there are other beneficial 
analytes potentially determinable with the reagent. Spectral responses of the reaction 
have demonstrated positional and enantio-specificity potentially allowing determination 
of cis vs trans and conjugated double bond isomers. The presence of conjugated double 
bonds is indicative of oxidative stress, and oxidative stress is associated with a variety of 
diseases in humans from atherosclerosis to diabetes. With all of the disease implications 
of the known analytes detected by this assay when combined with the known capability 
of the assay to cluster diabetics from a set of 100 normal and dyslipidemic patients 
(unpublished results) further emphasizes the potential of the assay as an alternative 
routine clinical assay. 
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Mixture Determination 
Introduction 
In order to determine the components of a mixture from a spectrum of the mixture 
a multivariate analysis method must be used. The simplest of the multivariate analysis 
methods is MLR. In MLR, the components of the mixture and the molar extinction 
coefficients of all components must be known. In the application of the chromogenic 
reaction for analysis of serums, the components absorbing the spectra are known. Once 
calibration data is determined for the full spectrum of each component, MLR should 
produce an accurate result for the concentration of each component. 
Studying synthetic mixtures is the first approach to the development of a real 
calibration system for the analysis of serum spectra can be developed. This study uses 
mixtures of lipids at concentration percentages of each component corresponding to the 
amounts found in actual serum samples. MLR analysis of the synthetic mixtures is then 
used to determine the feasibility of such a calibration system for real samples. 
Multiple Linear Regression 
MLR is the most basic of the multivariate analysis methods. The technique 
involves solving linear equations to determine thevconcentrations of the components that 
compose a mixture. The technique is accurate and resilient if all components of the 
mixture are known and appropriate calibration data are available for each component. In 
multiple linear regression, the dependent variable is related to a group of independent 
variables. For systems obeying Beer's law: 
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A= abc (4) 
Where A is the absorbance, a is the molar extinction coefficient, b is the pathlength and c 
is the concentration of the absorbing species. The dependent variable is the absorbance 
(A) at any wavelength. The absorbance (A) of a mixture is dependent on the sum of 
absorbance contributions from all of the components at that wavelength: 
Here b is a consistent pathlength of 10 mm. The above calculation can be done at all 
wavelengths by solving the simultaneous linear equations, and is easily achieved using 
matrix algebra. In matrix form equation 2 becomes: 
A=Xc (6) 
Where A is the spectral response from the mixture at all wavelengths, X is the molar 
absorptivity matrix for all components of the mixture at all wavelengths ( also known as 
the K matrix) and c is equal to the molar concentration vector. 
To determine the concentration for each component given the spectra A, solve 
equation ( 6) algebraically: 
(7) 
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In matrix algebra, the inverse of a non-square matrix does not equal to the algebraic 
inverse. It is necessary to calculate a "pseudo-inverse" instead. The pseudo-inverse is 
equal to: 
x-1 = (X'Xr1 X' (8) 
Where X' is the transpose of the matrix X. Substituting (5) into (4), we get the solvable 
equation: 
(9) 
In spectroscopic determinations, equation (9) is adequate if the components are 
present in large enough quantities to contribute to the resulting spectrum. In the analysis 
of PUF A at concentrations found in "normal" sera, some of the components are present 
in exceedingly small amounts. When equation (6) was used in the analysis the resulting 
concentration vector contained values less than zero. The Matlab function lsqnonneg 
does multiple linear regression analysis while avoiding errors caused by fitting a curve 
with data that is not significantly represented in the spectra. Lsqnonneg works by doing 
the minimization of the residual between the actual and calculated spectrum defined as; 
norm(CxX -d) (10) 
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Where C is the K matrix, d is the spectrum that is being fitted, and X is the concentration 
result of the lsqnonneg calculation. C times X creates a theoretical spectrum representing 
the concentrations determined by MLR. 
For lsqnonneg the values in X are required to be greater than zero. The residuals 
between the calculated spectra and the actual spectra were evaluated as; 
Y = norm(Cxlsqnonneg(C,d)-d) (11) 
Where C is the K matrix, d is the spectrum that is being fitted, and Y is the residual 
between the two. 
Negative outcomes influence the results for components that are in larger amounts 
and are adequately represented in the spectrum being analyzed. Lsqnonneg interprets 
negative results as "out of range" and automatically removes the absorptivity data for 
those components from the calculation and recalculates without these data, thus relying 
entirely on the remaining components of the K matrix. The resulting .concentration 
matrix has a zero in place of any negative values. The resulting solutions for the 
remaining components give a poorer fit to the calculated curve but relieve errors 
associated by the use of negative concentration values. 
The K matrix must contain linearly independent vectors. If the K matrix does not 
contain linearly independent vectors separation of the individual components would not 
be possible. In this work, the K matrix was determined to have the rank equal to the 
number of matrix columns (7), which indicates that the columns of the K matrix 
adequately represent unique components. 
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Methods 
Mixture Preparations 
Mixtures of the seven most common lipid components, methyl linoleate, methyl 
linolenate, methyl arachidonate, methyl eicosapentaenoate, methyl docosahexaenoate, 
methyl conjugated linoleate, and free cholesterol were created by approximating the 
percentages of the PUF As present in what were considered to be "normal" sera. Stock 
solutions for each PUF A, based on these percentages, were made with a maximum total 
PUF A concentration equal to 0.02 M. The total concentration of 0.02 M was chosen so 
that the spectral response in the lower wavelengths would be between 0.2 and 0.9 
absorbance units. The concentration of cholesterol used was also approximated to that 
found in a "normal" serum. Stock solutions were first made by dissolving the analyte in 
chloroform. The chloroform in the mixture was then evaporated under a stream of 
nitrogen. The resulting oily samples were then mixed with 1.0 mL pure AC and the 
reaction was initiated by 40 µL PA. Absorbance data were measured at 15 minutes into 
the reaction. 
Ratios of PUF A in "normal" sera were calculated using references that summarize 
human population fatty acid profiles data.44• 169' 170 Percentages were determined by 
dividing the concentration of the individual PUF A by the total PUF A concentration. 
Only PUF A were considered, saturated and monounsaturated fatty acids were not 
incorporated into the data. 
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Reaction of Mixtures with Perchloric Acid Catalyst 
Analysis was conducted by adding 2, 5 or IO µL of each proportional analyte 
stock solution to a 13 X 100 mm borosilicate disposable test tube. The chloroform was 
removed with a stream of nitrogen. Pure AC (1.0 mL) was added to the analyte mixture. 
The reaction was initiated by the addition of 40 µL PA. The reaction timer was started 
immediately after addition of catalyst. The reaction was energetic thus caution was taken 
to avoid bumping. The reaction was mixed by hand vortexing for IO seconds and then 
either placed in the cuvette for kinetic determination over 20 minutes or develop in the 
tube to later be analyzed at the 15-minute endpoint. Following maturation in the test tube 
the solution was transferred to the cuvette with a glass Pasteur pipette and full spectral 
data (350-800 nm) were collected. 
. Script Calculation Description 
The determination of the mixtures was done by automating the calculation 
through a matlab m-file script. The script is in Appendix A. The script analyzes the 
spectra using data at wavelengths from 350 to 650 nm to calculate all seven of the known 
components especially the two most prevalent components ( cholesterol and methyl 
linoleate ). It then calculates the theoretical spectra of both cholesterol and linoleate 
based on the calculated concentrations and the molar extinction coefficients for all 
wavelengths. Difference spectra are calculated by subtracting the theoretical cholesterol 
and linoleate spectra from the original spectra. The difference spectra are then 
determined for all remaining components in a second iteration utilizing a K matrix that 
excludes data for cholesterol or linoleate. By doing the spectral difference and a second 
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calculation, it was anticipated the amount of information determinable from any given 
spectra would be increased. 
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Results and Discussion 
The chemical assay has been demonstrated to have potential use in the analysi~ of 
lipids in sera. Experimental investigation into the use of the chemical assay for the 
analysis of blood lipids was done utilizing mixtures containing seven blood lipid 
components at physiologically correct concentrations. The results of multi-linear 
regression of these mixtures representing.serum concentrations of PUFA and cholesterol 
are encouraging. The power of quantitative analysis of sera depends on the ability to 
quantify all PUF A independent of the concentrations found in sera. The more highly 
unsaturated PUF A such as EPA and DHA are found at the lowest concentrations and are 
of the most importance physiologically. The ability to quantitate all PUF A real time 
could prove a useful routine assay containing information relevant to modem diseases. 
This notion is supported by the ability to cluster out diabetics from a group of 100 
subjects including dyslipidemic patients. 
The samples were run independently and the results were independent for each of 
the samples. Each sample was recorded at 15 minutes into the reaction over the range of 
350-800 nm. The samples were determined by MLR analysis using a matlab script as 
presented in Appendix A. The results of the MLR analysis included the residual for each 
calculated spectrum. The actual concentrations and MLR determined concentrations of 
the stock solutions are presented in Table 3. Observing this table, it is clear that the MLR 
analysis is not ideal for the determination of all PUF A in the mixtures. Indeed, there is a 
recurring theme throughout the mixture sets that the DHA and EPA concentrations are 
not accessible to the MLR calculation. From Table 2, the stock concentrations of DHA, 
EPA and methyl linolenate are all four times lower than methyl arachidonate and 15 
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times lower than methyl linoleate. It is likely that the inconsistencies in the 
determination of these PUF A are due to the low concentrations at which they are found. 
This result does not eliminate the possibility of utilizing this method for the full 
determination of PUF A m sera. Alternative methods. including increasing the 
concentration of sera in the reaction in order to get better resolution in the low 
wavelengths or analysis methods which take advantage of the information contained in 
the kinetics plots of the chromogenic reactions may prove MLR useful for the 
determination of real samples. 
Table 2. Polyunsaturated fatty acids concentrations. 
Fattv acid %PUFA stock cone 
leic 75 0.015 M 
lenic 3.4 0.001 M 
arach 17 0.004 M 
DHA 2.8 0.001 M 
EPA 1.4 0.001 M 
total= 0.022 M 
The results also indicate that arachidonate is not as accurate as the linoleate and 
cholesterol values. This is likely due to the three times smaller concentration. This lower 
concentration does not allow adequate resolution of the concentrations. The "sum" 
values on the last two columns of the table are the sum of all PUF A determined by MLR 
analysis and the sum of the actual expected concentrations. It is clear from these values 
that the nonnegative MLR is detecting and quantitating the majority of the PUF A species 
. present but is not able to separate the values into discrete concentrations. 
Some of the mixtures included conjugated methyl linoleate. The resulting 
. concentrations are sometimes determinable but at the lowest concentrations, MLR returns 
a zero result. Conjugated methyl linoleate concentrations were lower than 5 X 10-7 M in 
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samples 6,7,13, and 14, and were not determined by MLR analysis. Overall MLR 
determinations worked well for methyl linoleate, cholesterol and conjugated methyl 
linoleate concentrations. Conjugated methyl linoleate was more readily determinable at 
relatively high concentrations. 
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Table 3: Results including actual and MLR determined concentrations for all seven 
components (M) 
leic- leic- lenic- lenic- arach- arach- DHA- DHA-
actual MLR actual MLR actual MLR actual MLR 
1 2.9E-05 1.5E-05 9.6E-06 2.1E-05 3.8E-05 6.1E-05 9.6E-06 0 
2 7.2E-05 4.6E-05 9.6E-06 6.1E-05 3.8E-05 4.6E-05 9.6E-06 0 
3 1.4E-04 8.6E-05 1.9E-06 1.3E-04 3.8E-05 6.9E-07 9.6E-06 0 
4 1.4E-04 9.4E-05 4.8E-06 1.3E-04 3.8E-05 0 9.6E-06 0 
5 1.4E-04 9.9E-05 9.6E-06 1.0E-04 7.7E-06 0 9.6E-06 0 
6 1.4E-04 9.2E-05 9.6E-06 1.4E-04 3.8E-05 0 1.9E-06 0 
7 1.4E-04 9.8E-05 9.6E-06 1.4E-04 3.8E-05 0 4.8E-06 0 
8 1.4E-04 9.6E-05 9.6E-06 1.5E-04 3.8E-05 0 9.6E-06 0 
9 1.4E-04 8.6E-05 9.6E-06 1.6E-04 3.8E-05 0 9.6E-06 0 
10 1.4E-04 9.5E-05 9.6E-06 1.6E-04 3.8E-05 0 9.6E-06 0 
11 1.4E-04 9.1E-05 4.8E-06 1.1E-04 3.8E-05 0 4.8E-06 0 
12 0 0 1.9E-06 0 3.8E-05 6.2E-05 4.8E-06 0 
13 0 0 4.8E-06 0 7.7E-06 3.1E-05 9.5E-06 0 
14 1.4E-04 7.4E-05 0 9.4E-05 1.9E-05 0 1.9E-06 0 
15 7.2E-05 5.0E-05 9.5E-06 5.1E-05 0 0 4.8E-06 0 
16 2.9E-05 2.0E~05 4.8E-06 4.2E-05 3.8E-05 3.6E-05 0 0 
17 0 0 1.9E-06 0 1.9E-05 3.9E-05 9.5E-06 0 
18 7.2E-05 4.5E-05 9.5E-06 9.3E-05 3.8E-05 2.6E-05 1.9E-06 0 
19 2.9E-05 2.2E-05 9.5E-06 4.1E-05 3.8E-05 6.0E-05 4.8E-06 0 
20 1.4E-04 6.6E-05 4.8E-06 9.0E-05 7.7E-06 0 9.5E-06 0 
21 1.4E-04 0 9.6E-06 2.5E-04 3.8E-05 0 9.6E-06 0 
22 1.4E-04 1.05E-04 9.6E-06 1.5E-04 3.8E-05 0 9.6E-06 0 
23 1.4E-04 1.46E-04 9.6E-06 8.3E-05 3.8E-05 3.4E-05 9.6E-06 0 
24 7.2E-05 0 4.8E-06 3.4E-04 1.9E-05 0 4.8E-06 0 
25 7.2E-05 0 4.8E-06 2.5E-04 1.9E-05 0 4.8E-06 0 
26 7.2E-05 5.0E-05 4.8E-06 1.1E-04 1.9E-05 0 4.8E-06 0 
27 7.2E-05 5.5E-05 4.8E-06 7.5E-05 1.9E-05 0 4.8E-06 0 
28 7.2E-05 4.7E-05 4.8E-06 9.3E-05 1.9E-05 0 4.8E-06 0 
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Table 3. Results including actual and MLR determined concentrations for all seven 
components (M) (cont.) 
EPA- EPA- chol- chol- conj- conj- sum- sum-
actual MLR actual MLR actual MLR actual MLR 
1 9.6E-06 0 7.2E-05 7.4E-05 0 0 9.6E-05 9.6E-05 
2 9.6E-06 0 7.2E-05 7.6E-05 0 0 1.4E-04 1.5E-04 
3 9.6E-06 0 7.2E-05 7.7E-05 0 0 2.0E-04 2.2E-04 
4 9.6E-06 0 7.2E-05 7.SE-05 0 0 2.1E-04 2.2E-04 
5 9.6E-06 0 7.2E-05 7.4E-05 0 0 1.SE-04 2.0E-04 
6 9.6E-06 0 7.2E-05 7.2E-05 0 0 2.0E-04 2.3E-04 
7 9.6E-06 0 7.2E-05 6.SE-05 0 0 2.1E-04 2.4E-04 
8 1.9E-06 0 7.2E-05 7.3E-05 0 0 2.0E-04 2.5E-04 
9 4.SE-06 0 7.2E-05 6.6E-05 0 0 2.1E-04 2.5E-04 
10 9.6E-06 0 7.2E-05 6.7E-05 0 0 2.1E-04 2.6E-04 
11 1.9E-06 0 7.2E-05 6.9E-05 0 0 1.9E-04 2.0E-04 
12 9.5E-06 0 7.2E-05 7.1E-05 0 0 5.4E-05 6.2E-05 
13 4.SE-06 0 7.2E-05 7.4E-05 0 0 2.7E-05 3.1E-05 
14 9.5E-06 0 7.2E-05 6.BE-05 0 4.1E-06 1.7E-04 1.7E-04 
15 1.9E-06 0 7.2E-05 7.6E-05 0 0 8.SE-05 1.0E-04 
16 4.SE-06 0 7.2E-05 7.2E-05 0 0 7.6E-05 9.9E-05 
17 0 0 7.2E-05 7.2E-05 0 0 3.1E-05 3.9E-05 
18 9.5E-06 0 7.2E-05 7.3E-05 0 0 1.3E-04 1.6E-04 
19 9.5E-06 0 7.2E-05 7.5E-05 0 0 9.1E-05 1.2E-04 
20 4.SE-06 0 7.2E-05 7.6E-05 0 1.4E-05 1.7E-04 1.7E-04 
21 9.6E-06 0 7.2E-05 6.1E-05 4.SE-05 5.1E-05 2.6E-04 3.0E-04 
22 9.6E-06 0 7.2E-05 7.4E-05 4.SE-05 0 2.6E-04 2.5E-04 
23 9.6E-06 0 7.2E-05 7.2E-05 1.9E-05 0 2.3E-04 2.6E-04 
24 4.SE-06 0 1.4E-04 1.2E-04 9.6E-05 6.0E-05 2.0E-04 4.0E-04 
25 4.SE-06 0 1.4E-04 1.3E-04 4.SE-05 3.6E-05 1.5E-04 2.9E-04 
26 4.SE-06 0 1.4E-04 1.4E-04 4.SE-05 0 1.5E-04 1.6E-04 
27 4.SE-06 0 1.4E-04 1.5E-04 9.6E-05 0 2.0E-04 1.3E-04 
28 4.SE-06 o. 1.4E-04 1.4E-04 1.9E-05 0 1.3E-04 1.4E-04 
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Analysis of errors was used to discriminate any obviously erroneous data in the 
original pool. It was decided that any spectra, which had a 520 nm absorbance of 0.02 
absorbance unit below the expected value for the actual concentration, would be removed 
as erroneous. 
The MLR analysis concentrations are used to create a "theoretical" spectrum that 
is used in the optimization of the calculation. Outside the MLR calculation this spectra, 
when compared to the original empirical spectra gives some idea of how well the MLR 
model fits the spectrum. Mixture 3 was analyzed to determine the MLR spectrum and the 
difference between the empirical spectrum and the MLR spectrum (Figure 17(including 
insert)). The differences are minimized in the lsqnonneg calculation process. 
There seems to be a consistent shift in the 520 nm maximum during the 
calculation of the MLR spectrum. It is not clear why this occurs in the MLR calculation 
but not in the empirical spectra. The determination of the absorbance spectrum for pure 
cholesterol using the K matrix from the MLR analysis does not lead to the 520 nm shift. 
However, upon addition of other components into the concentration vector the shift 
occurs. 
During the processmg of the mixtures, the diluted stocks containing the 
approximation to physiological amounts of each component were run. They were done 
with 10 µL of the each one in the normal AC I PA reaction. The results give an 
indication as to the approximate absorbances occurring due to each concentration at the 
maximum quantities they were used. They are presented in (Figure 18). The low 
concentrations of methyl linolenate, DHA, and EPA create low absorbance spectra with 
increasing associated errors. The lowest concentration of methyl conjugated linoleate 
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give a similar absorbance as the highly unsaturated fatty acids: This gives some insight 
into the inability to resolve the lower methyl conjugated linoleate concentrations by MLR 
analysis. 
The results of the MLR analysis of mixtures are not as good as expected. It was 
hoped that the analysis could recover reliable data for all PUF A species including those at 
lower concentrations. The determination using a pseudo-inverse K-matrix gave negative 
values this is attributed to errors in determining the concentrations. This is potentially 
due to low signal to noise at the levels the more highly unsaturated PUF A occur. It also 
may be due to errors associated with Matlab numerical determinations used for the 
analysis. 
Matlab uses numerical methods to determine the results for matrix calculations. 
These types of calculations result in unavoidable errors. If the program uses iterative 
routines to calculate values, the error accumulates. This type of error is only avoidable if 
full control of the calculation process is available to the programmer. Matlab does not 
allow that level of control. If from equation (7) the K-matrix and the concentration 
vector are known, an absorbance spectrum is determinable. This "theoretical spectra" 
can then be used in MLR with the same K-matrix to achieve the concentration vector 
back again. There should be no variation between the theoretical and determined 
concentrations. When this type of calculation is used for the determination of errors 
associated with the calculations, the calculation using the standard pseudo-inverse has a 
small associated error for concentration values down to 1 X 10-14 M. The pseudo-inverse 
calculation also gives negative responses, however, leading to erroneous results. The 
preferred lsqnonneg script, for the determination of concentration without the errors due 
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to negatives, results in a similar error as the standard calculation down to a concentration 
of about 4 X 10-7 M. At and below this concentration the mathematical approach breaks 
down. The resulting values are not representative of the ''theoretical" concentration 
originally put into the calculation. This result may be due to cumulative errors associated 
with the iterative calculation. These errors may be circumvented by increasing the 
concentration in the actual analysis to give high absorbance values in the lower 
wavelengths. It may also be overcome by more rigorous programming control of errors. 
Also important is that the MLR calculation is accounting for the background 
correction associated with the reagent itself. At 15 minutes, the maximum absorbance of 
the background is 0.02 absorbance units at 350 nm. This is approximately a five percent 
error for an absorbance of 0.4 absorbance units. The error diminishes for PUF As as the 
wavelengths increase. 
The error, between the MLR determined concentrations and the theoretical 
concentrations, also includes experimental errors. These errors are significant because 
the volumes used were small and many measurements were made. The samples were 
also made to maximize variation in the components not to assure accuracy through 
repeated spectral measurements. 
Despite difficulties in the calculation of the concentrations found in the 
spectroscopic analysis of mixtures, the utility of the assay is proven. The method in its 
first generation form can determine cholesterol and linoleic acid at ·their natural 
concentrations as well as conjugated linoleic acid at elevated levels. These data 
combined represent a new era of rapid PUF A determinations that has the potential to 
contribute meaningful information to diagnostic determinations made today. 
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Figure 17. Mix 3 empirical spectrum (A) with overlaid MLR determined 
spectrum (B). insert: Difference between empirical spectrum minus MLR 
determined spectrum. 
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Figure 18: Overlaid spectra of all seven components at the concentrations on table 
4. All were created by using 10 µl chloroform sample plus 1.0 ml acetyl chloride 
catalyzed with perchloric acid. Including: equivalence of 10 µl of A) 0.01 M 
methyl conjugated linoleate B) 0.0075 M cholesterol C) 0.015 M methyl linoleate 
D) 0.00034 M methyl arachidonate E) 0.001 M methyl conjugated linoleate 
F) 0.00028 M methyl EPA G) 0.00078 M methyl DHA H) 0.00068 M methyl 
linolenate I) 0.0001 M methyl conjugated linoleate 
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Dietary Intervention Study 
Introduction 
The diet of a 28-year-old obese Caucasian male volunteer was modified from a 
high fat diet to a low fat diet. Serum lipids were monitored with regularity over a 4-
month period. The dietary intake of the subject was monitored and analyzed for lipid 
content. The serum lipid modification was also monitored using the novel chromogenic 
reaction discussed earlier, which is quantitative for cholesterol and PUF As. The weight 
of the subject was also monitored. 
The expected result of a low-fat dietary intervention is lowered lipids including 
cholesterol and TG concentrations. This was observed and an attempt was made to also 
monitor the PUF A content of the serum. The reactions were performed using a modified 
reagent that was a mixture of 3/2 AC I DCE, plus PA as catalyst. This decision was made 
in order to make comparisons between this study and a South African study in which 
diabetics were found to be separated from 100 "normal" and dyslipidemic patients in 2-D 
and 3-D clustering analysis. 
The subject self-monitored his diet for fats, cholesterol, and calories following 
recommendations from the nutritionist at Oklahoma State University Seretean Wellness 
Center. Subscribing to a diet that preferred PUFAs over saturated fatty acids; the subject 
consumed more fish and chicken instead of beef. Simple sugars were also avoided as a 
means of maintaining low caloric intake. The diet of the subject was recorded in a daily 
journal, which included food type and portion size. The diet was then analyzed using an 
Internet database. The subject did not undertake an exercise program for the duration of 
the trial. 
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The hypothesis being tested was the ability of the assay to be used in the tracking 
patient responses to intervention studies. Such studies are particularly well suited to this 
assay as the cost per analysis is low. Furthermore, quantification of the serum 
components is not entirely necessary during the study, as the differences in the spectra 
during the study are more than adequate to determine the effectiveness of the treatment. 
As described in the Chapter I and in previous research, the assay is linearly dependent on 
the serum lipid components: cholesterol, linoleic acid and conjugated linoleic acid. The 
assay can potentially be modified to increase the sensitivity to include data for the PUP A 
found at lower concentrations. Eventually the quantitative determination of all PUP A, 
including conjugated dienes will allow the reaction to supplement or supplant currently 
used methods in routine lipid analysis of human sera. 
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Methods 
Serum Sampling 
Samples were drawn at the Oklahoma State University Wellness Center and 
analyzed at the Regional Medical Laboratory. The samples were taken as venous draws 
from the arm into two Vacutainer™ red-stoppered serum separation tubes. These tubes 
use a density gel to assist in separation of. the serum from the red blood cells. The 
samples were allowed to stand at room temperature for 30 min to allow clotting factors to 
solidify. The vacuum tube was then centrifuged at 5,000 rpm for 15 min to allow 
separation in a tabletop centrifuge (Fisher Centrific model 228). One of the tubes was 
submitted to the Regional Medical Laboratory and the other was utilized for the chemical 
analysis in the Oklahoma State University Department of Chemistry. The samples for 
chemical analysis were stored in 10 mL vials with screw caps. 
Reaction of Serum with Perchloric Acid Catalyst 
Analyses were done by adding the usual 10 µL of analyte ( serum) to the bottom of 
a 13 X 100 mm borosilicate disposable test tube. Acylating agent, pure AC/DCB (1.0 
mL ), was added to the analyte. The reaction was initiated on careful addition of 40 µL 
PA, and the reaction timer started immediately. Precautions and mixing by vortexing 
were done as before. Protein precipitants were removed by centrifugation for 3 minutes 
at 3400 rpm. The sample was separated from the precipitate pellet and either placed in 
the cuvette for kinetic determination or allowed to develop inside a separate test tube 
until the 15-minute endpoint was reached. Full spectral data (350-800 nm) were 
collected as before. 
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A minimum of three samples of each serum sample was run. The full spectral 
data (350 - 800 run) were stored for all reaction times between five and 20 min. Data 
before 5 min were not available due to the centrifugation process. 
It is important to note that the data were taken with a modified reagent. The 
reagent contained 60% AC to 40% DCE. This reagent was used so the subject's data 
could be compared to previously collected cross-sectional clinical data. 
Clinical Laboratory Results 
The clinical laboratory used standard enzymatic reaction and Friedewald 
approximations (see Chapter III introduction) to determine TC, TG, HDL-C and LDL-C. 
The clinical laboratory also returned results for trace analytes such as sodium, calcium 
and liver enzymes (see results and discussion). 
MLR Analysis Methods 
Analysis of the serum samples included the use of the MLR method described 
earlier in this chapter. The cholesterol, linoleic acid, and docosahexaenoic acid 
concentrations for the subject over the trial was determined from the chromogenic 
reaction spectra using the MLR method. The modified script file for the analysis of 
serum samples is presented in the Appendix B. 
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Results and Discussion 
Over the course of the study, the TC was progressively lowered from 282 mg/dL 
to a minimum of 172 mg/dL (Figure 19(B)). The LDL-C concentration was also lowered 
from 186 mg/dL to a minimum of 85 mg/dL (Figure 19(C)). The HDL-C concentration 
was lowered slightly during the study from 47 mg/dL to a minimum of 33 mg/dL (Figure 
19(D)). TG values were lowered from 392 mg/dL to 155 mg/dL at the lowest point 
(Figure 20(A)). The subject's weight was lowered from 285 lbs. to 252 lbs. at the lowest 
point 
The alteration of the LDL-C concentration to the HDL-C concentration is of 
interest in that the lowered LDL-C and/or elevated HDL-C concentration is indicative of 
diminishing risk of atherosclerosis and heart disease. In this dietary intervention study 
the LDL-C/HDL-C concentration ratio as determined by the standard clinical assay 
decreased over the duration of the study from 4.2 to a minimum of2.2 (Figure 21). 
Other serum values measured included glucose, BUN, creatinine, sodium, 
potassium, chloride, bicarbonate, anion gap, uric acid, calcium, phosphorus, protein total, 
albumin, bilirubin total, iron, ALK PHOS, LD. None of these analytes altered 
significantly during the dietary trial. 
The liver enzymes aspartate aminotransferase (AST (SOOT)), alanine 
aminotransferase (ALT (SGPT)), and gamma-glutamyltransferase (GGT) were also 
determined during the dietary trial and were all above normal values initially. Elevated 
liver enzymes are a sign ofliver damage. There are a number of causes for elevated liver 
enzyme levels. The use of cholesterol lowering statin drugs can cause increase in free 
liver enzymes. The subject was not using such medication. Infectious hepatitis can cause 
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increased liver enzyme levels. The possibility of infectious hepatitis was eliminated by 
testing for the presence of such viruses. The possible diagnosis from the subject's 
personal physician was either fatty liver or liver cancer. The recommended diagnosis 
verification method was liver biopsy. Fatty liver as the alternative diagnosis would be 
evident in increased fat cells in the liver biopsy. The subject decided to postpone liver 
biopsy and tracked the liver enzymes as the diet was changed. The values for AST 
(SGOT) were lowered over the trial from 86 to a minimum of 19. ALT (SGPT) went 
from 171 to 29. The levels of GGT dropped from 100 to a minimum of 31. All three 
liver enzymes dropped into the normal range over the course of the study. These results 
indicated that nonalcoholic fatty liver was the cause of the elevated liver enzymes and 
that the dietary regimen the subject was using acted as an effective treatment for that 
disorder. Interestingly, the process of liver biopsy, while routine, is an invasive 
technique with risks associated with such techniques. The possibility of an alternative 
noninvasive method of diagnosis was not recommended as an option. 
The value of the absorbance at 520 nm was adjusted by multiplying by a constant 
so the average of the adjusted 520 nm values is equal to the average values of the 
cholesterol concentration determined by the standard clinical assay in mg/dL. The value 
of the constant is 437. The clinically measured value of cholesterol overlays the adjusted 
value of the 520 nm peak for the subject over the time of the study (Figure 19(A)). This 
indicates there is a close relationship between the cholesterol value and the 520 nm value, 
and is expected given the understanding that the majority of the 520 nm peak comes from 
the reaction with cholesterol. 
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The 362 nm absorbance value was adjusted by multiplication by a constant (908). 
The result is that the average of the adjusted 362 nm absorbance is equal to the average 
TG values determined by the standard clinical assay in mg/dL. The adjusted 362 nm 
values overlay the values of the TG concentration determined by the standard clinical 
assay (Figure 20(A and B)). Particularly interesting is the upturn of both the clinical TG 
values and the adjusted 362 nm absorbances. This indicates there is a real increase near 
the end of the study. 
The enzymatic method for the determination of TG only detects the glycerol 
portion of the triacylglycerol molecule. Concentrations of TG are not equivalent to a 
particular species of fatty acid. Since there are saturated, monounsaturated and PUF A 
attached to the glycerol. The fact that the TG concentrations mirror the adjusted 362 nm 
values is representative of the ubiquitous presence of the PUF A in serum components. 
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Figure 19. Overlaid graph of all clinical data with adjusted absorbances from 
chemical assay A) 520 nm absorbance adjusted by a constant (437) so the average of 
the absorbances over the trial is equal to the concentrations of cholesterol in mg/dL 
by standard clinical assay B) cholesterol in mg/dL by standard clinical assay C) LDL 
cholesterol concentration determined by standard clinical assay D) HDL cholesterol 
concentration determined by standard clinical assay. 
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Figure 20. Overlaid graph of A) triglyceride concentration mg/dL B) absorbance at 
362 nm adjusted by a constant (908) so that the average adjusted 362 nm absorbance 
value was equal to the average triglyceride concentration in mg/dL. 
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Figure 21. Graph demonstrating decrease in the LDL/HDL cholesterol 
concentration ratio, determined by the standard clinical method, for the 
duration of the intervention trial. Lower LDL/HDL ratio is associated with a 
decrease in the risk of atherosclerosis and heart disease. 
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MLR results 
The method developed for the determinations of lipid components of mixtures 
presented earlier in this thesis was applied to the determination of lipids in real sera. The 
reagent used for the determination of the sera is modified from pure AC to 60% AC 40% 
DCE. The results for the determination of sera using the calibration data from the 
mixture section are therefore systematically shifted. However, the comparison between 
the values as they change in this intervention study should are independent of this 
systematic error. 
The relationship between the TC determined by the enzymatic clinical laboratory 
method and the value by MLR are linearly correlated (Figure 22). The clinical value was 
converted to molarity in the assay solution by standard conversions. The linear cross-
correlation plot of the two sets of values against each other has a slope of 0. 7824 and R 
squared of 0.9249. They-intercept of this plot is 1X10'5. 
The TC values determined by the standard clinical assay and the MLR analysis of 
the chromogenic assay data were plotted versus the days of the study. The correlation 
between the clinical data and the chemical assay data is good. Both the clinical data 
(Figure 23(B)) and the MLR data (Figure 23(A)) decrease early in the intervention 
coming to a plateau around 100 days into the study. Both data sets indicate a slight 
increase in cholesterol towards the end of the study. 
Linoleic acid was also determined in the MLR analysis of the chromogenic 
chemical assay spectra. Interestingly linoleic acid was progressively lowered during the 
study. However, the ratio between the linoleic acid and cholesterol determined by MLR 
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analysis seems to be constant for the duration of the study until the end where the ratio 
increases significantly (Figure 24). This increase occurs in the region of the study at 
which TG determined by the standard clinical assay increases, which suggests that the 
increase in the standard clinical assay later in the study is associated with a variation of 
fatty acid composition while the initial lowering of the lipid levels is not. 
There is a correlation between TG and the values for the PUF As found by MLR. 
In the plot of the overlaid values for TG determined by the standard clinical assay and the 
sum of the concentrations oflinoleic acid, DHA (possibly highly unsaturated PUPA), and 
conjugated linoleate versus the days of the study indicates the relationship. Both the 
clinical TG value (Figure 25(A)) and the value of the MLR determined combined 
concentrations of the PUPA (Figure 25(B)) decrease at the beginning of the study, reach 
a minimum around 100 days and increase at the end of the study. 
When the TG values determined by the standard clinical assay and the sum of the 
concentrations of linoleic acid, DHA (possibly highly unsaturated PUF A), and 
conjugated double bond are plotted versus the TG concentrations in mg/dL, a linear 
correlation is seen (Figure 26). The MLR determined PUF As values were multiplied by 
a constant to bring the average of all the values into the range of the average of all of the 
TG concentrations. The value needed to normalize the two sets of data was 4.25X106• 
The result of least squares linear regression was a slope of 0.5088 with R squared of 
0.7087 and y intercept of 124.28. The very high y-intercept is a consequence of the 
variability in the molecular weight of the "average" PUF A in triglyceride structures. The 
residuals of the MLR calculations are presented on (Figures 23 and 24). 
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Figure 22. Cross-correlation plot demonstrating linear relationship 
between cholesterol concentrations determined by MLR analysis of the 
chemical assay spectra and the cholesterol concentration determined by 
the standard clinical assay. The linear regression of the cross-correlation 
plot describes the best fit line as having a slope of 0.7824 with R squared 
of 0.9249 and a y intercept of lXl0-5• 
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Figure 23. Overlaid graph A) cholesterol concentration determined by the MLR 
analysis of the chemical assay spectra and B) the cholesterol concentration 
determined by the standard clinical assay .. This demonstrates the close relationship 
between the determination of cholesterol by MLR analysis of the chemical assay and 
the determination of cholesterol by the standard clinical assay. 
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Figure 24. Graph demonstrating the steady nature of the ratio of 
linoleic acid determined by MLR analysis of the chemical assay 
spectra and the cholesterol concentration determined by MLR analysis 
of the chemical assay spectra. The upturn of the ratio between linoleic 
acid and cholesterol at the end of the trial is particularly interesting. 
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Figure 25. Overlaid graph of A) triglyceride concentrations 
determined by the standard clinical assay and B) the sum of 
concentrations of linoleic acid, DHA, and conjugated diene 
concentrations in molarity determined by MLR analysis of the 
chemical assay spectra adjusted by multiplication of integer (4.25Xl06) 
to make the average of the concentration of the summed PUF A equal 
to the average of the triglyceride values determined by the standard 
clinical assay in mg/dL. 
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Figure 26. Cross-correlation plot of the adjusted value of the sums of 
linoleic acid, DHA, and conjugated diene determined by the MLR 
analysis of the chemical assay spectra versus the ) triglyceride 
concentrations determined by the standard clinical assay in mg/dL 
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Summary 
The determination of lipids in blood is routinely used for the analysis of 
dyslipidemias and risk for CAD, the leading cause of death in the United States. Results 
presented in Chapter II give a clear indication of the utility of the reagent for (I) the 
quantitative determination of the major lipids in concentrations consistent with those 
found in sera; (2) the ability of the data available from the chromogenic reaction to 
correlate and consequently model the data determined by routine methods currently being 
used and (3) the potential utility of quantitative determination of lipids in the sera for 
routine monitoring of patients and the diagnosis of disease states. 
The ability to determine the concentration of major lipid components; cholesterol, 
linoleic acid and arachidonic acid from mixtures that have PUF A concentration ratios 
similar to sera is the first step toward an analytical method for the determination of all 
PUF A in sera by multivariate analysis. Good correlations are currently available with 
this first generation data analysis method. Future work will extend the boundaries to 
include all PUF As and the resultant lipid profiles will have important applications in 
screening patients for emerging disease risks. 
The observed consistency in the correlation between the values for the PUF As, 
represented by the 362 nm absorbance values with the standard clinically measured TG 
concentrations, was an expected result given the ubiquitous nature of the PUF A species 
throughout the chemical forms in which they occur in the blood. While the determination 
of "triglyceride" values is not possible with the PUF A concentration data available from 
the chromogenic reaction, the ability to monitor a patient's fatty acid variation in a 
longitudinal manner is demonstrated. Furthermore, there is strong evidence in the 
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literature that the concentration values of individual PUF A species are likely more 
important for determination of disease states than the collective value as represented by 
TG. 
The ability to quantitatively determine cholesterol, linoleic, arachidonic acid 
concentrations is indicative of the power the chromogenic reaction has in the analysis of 
lipids and the subsequent determination of disease states. Even in the preliminary 
methods presented here the quantitative determination of TC by MLR and the qualitative 
demonstration of acquiring information about fatty acids in the triglyceride form only 
available by enzymatic methods routinely used today for analysis is demonstrated. In its 
present state, the assay could be used for the monitoring of patients and the determination 
of relative change in PUF A and TC. 
The techniques used for the demonstration of the chromogenic reaction's utility 
took advantage of the unique spectra present in six of the seven components. The ability 
of the reagent combined with a multivariate analysis method to be perfected in the future 
will bring a new world of information to the physician's hands in minutes. 
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CHAPTER III 
CONCLUSIONS 
Chapter I shows the unique selectivity and quantitative nature of the chromogenic 
reaction. The chromogenic reaction of AC with unsaturated compounds catalyzed by 
Lewis or Bronsted acids is shown useful for the analysis of a variety of structural 
moieties. The emphasis of this thesis is on the determination of lipid components of sera. 
The reaction has potential in a variety of alternative applications. The ability of the 
reagent to not only be selective to for the unsaturated portion of the analyte but also the 
saturated portion supports the idea of analyzing more complex chemical structures. 
Broader applications are supported by the evidence presented in Chapter I where 
the reagent was used to produce chromogenic responses from a broad variety of 
compounds. Stoichiometric comparisons were made in order to understand the 
contributions each unique structural region contributes to the spectrum. The results 
indicate a highly selective reaction for both unsaturated and saturated structures. Molar 
extinction coefficients were determined by calibration curve analysis for some of the 
compounds. Linearity and limits of detection for these compounds confirmed the 
quantitative nature of the reaction. It was found that the spectral response of the various 
compounds to the reagent was related to the structural components of the compounds and 
. that the reagent also appeared to be selective to positional and stereo-variations. It was 
also demonstrated that the spectra for individual components in a mixture are strictly 
. additive and spectra from different chromophores in the same molecule are additive. 
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In analytical applications, the reaction could serve to detect the presence of 
contaminating unsaturated compounds that produce their own chromogenic response to 
the reagent. Accordingly, in. quantitative assays, the lack of a spectral response for a 
given pure compound may be indicative of non-chromogenic contaminants. 
Alternatively, the reagent could be used for quantitative determination of mixtures using 
multivariate analysis. In complex natural mixtures of PUF A for instance, the 
determination of the components would allow monitoring and management of the 
components. In areas such as plant oil processing or biodiesel production, this simple, 
cheap and automatable method of analysis could increase profitability and quality control 
in the manufacture process. Finally, the reaction has demonstrated selectivity for 
unsaturated structural moieties, which could be used for the analysis of unknown 
chemical structures. This could be useful in the combinatorial drug development where a 
particular moiety is expected, and the reaction is used for quality control of libraries. It 
could also be useful if a random structure development process is used to form a library 
and the chromogenic reaction is used to either screen for known useful or toxic moieties. 
A review of the· current methods used in lipids analysis was presented. The 
current paradigm was considered and developing methods were described to demonstrate 
the progressive nature of the field of lipoprotein analysis as the best methods are still 
being sought. The review also demonstrates the utility of fatty acid analysis. The 
relationships between PUF A and a variety of diseases are considered and the 
determination and use of PUF A values is described. The review also discussed the 
importance of being able to determine conjugated diene species in the analysis of 
oxidative stress related diseases. Overall the review describes the imperfect routine 
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methods currently used and develops an argument for the importance of a fast, 
economical alternative. 
The components of human blood lipids were among the compounds studied in the 
analysis of model compounds in Chapter I. In Chapter II, combinations of the blood 
lipids in ratios representing human serum were prepared and determined by MLR. 
Results for accurately analyzing the major lipids independently were generally good. 
The ability to determine the minor components was not as good as expected, and is partly 
due to experimental and calculation errors and partly due to the low concentrations of the 
minor serum lipid components. In the future analyses can be improved upon by using 
calculation methods that control the cumulative errors associated with the calculation, or 
possibly by increasing the concentration of the serum analyte in order to gain better 
information about the minor components in the sera. Alternatively, multivariate analysis 
methods capable of taking advantage of the absorbance data collected at 1 minute 
intervals throughout the reaction may increase both the selectivity and sensitivity. The 
analysis in its current form resulted in good data for the concentrations of cholesterol, 
linoleic acid, and elevated levels of conjugated linoleic acid. 
The application to a real patient was of interest as prior research shows an ability 
to cluster diabetics from a group of 100 patients, which included other dyslipidemics. In 
Chapter II, the utilization of the assay to monitor the response of a patient to dietary 
intervention is demonstrated. A 29-year-old obese Caucasian male was monitored as his 
diet was changed resulting in significant lipids lowering and lipoprotein concentration 
ratio alterations. Results indicated that while the LDL-C/HDL-C ratio was not detected 
in the chemical assay, the amounts of linoleic acid and TC were quantitated using the 
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MLR method developed on synthetic mixtures. Also, a linear correlation was shown to 
exist between the TG concentration in mg/dL and the linoleic acid concentration adjusted 
to mg/dL; a relationship that may be quantitative within biological variability. There was 
no evidence for the presence of conjugated linoleic acid in the sera. Future work may 
prove that quantitation of conjugated linoleic acid at serum concentrations is possible. 
This is significant in the study of in vivo oxidative stress. 
The chemical assay discovered in our laboratory is very flexible in its application. 
It shows selectivity to a variety of chemical moieties such as positional and enantiomeric 
isomers, which makes it useful for the analysis of unsaturated systems in quantitative 
analysis and quality control applications. It is novel; its closest rival, the L-B reaction, is 
significantly different in its reactive center e.g. L-B does not react with PUF A. 
Quantitation of blood lipids was conducted in synthetic mixtures and in real sera in order 
to gauge the usefulness of the assay (or sera analysis. Quantitative determinations of 
cholesterol, linoleic acid, and elevated levels of conjugated linoleic acid were possible in 
this first generation analysis. Simple manipulations can increase the detection limits by 
at least three times and improved MLR analysis programming should allow the assay to 
quantitatively determine all blood unsaturated components including conjugated dienes. 
The assay is inexpensive to conduct and is manageable in terms of chemical hazards. 
Overall, it has been demonstrated that the unique selectivity and quantitative ability of 
this reaction has the potential to revolutionize serum lipid .analysis. 
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APPENDIX A 
LSQNONNEG SCRIPT FOR MIXTURES 
load kmat450.txt 
load kmat650.txt 
load lin650.txt 
load chol650.txt 
forN=l:42 
name=['s' int2str(N) '.txt']; 
load(name); 
end 
clearN 
clear name 
forN=l:42 
name=['s' int2str(N)]; 
tn650=eval(name ); 
tn450=tn650( 1 :51 ); 
conc650 = lsqnonneg(kmat650,tn650); 
mlr=kmat650*conc650 
diffmlr=tn650-mlr 
X = conc650(6); 
cholspec650= X*chol650; 
X = conc650(1 ); 
linspec650 = X*lin650; 
totalspec = cholspec650 + linspec650; 
minuscholandlin = tn650 - totalspec; 
resid650 = norm(kmat650*conc650-tn650); 
X =minuscholandlin( 1: 51 ); 
conc450 = lsqnonneg(kmat450,X); 
resid450 = norm(kmat450*conc450-tn450); 
temp=['resid450s' ,int2str(N), ' = resid450']; 
eval(temp); 
temp=['resid650s' ,int2str(N), ' = resid650']; 
eval(temp); 
temp=['minuscholandlin650s' ,int2str(N), '= minuscholandlin']; 
eval(temp); 
temp=['conc650s' ,int2str(N), '= conc650']; 
eval(temp); 
temp=['conc450s' ,int2str(N), '= conc450']; 
eval(temp); 
temp=['cholspec650s' ,int2str(N), ' = cholspec650']; 
eval(temp); 
temp=['linspec650s' ,int2str(N), ' = linspec650']; 
eval(temp); 
temp=['cholandlins' ,int2str(N), '= totalspec']; 
eval(temp); 
temp=['mlr650s' ,int2str(N), ' = mlr']; 
eval(temp); 
temp=['diffmlr650s' ,int2str(N), '= diffmlr']; 
eval(temp); 
clear tn650 
cleartn450 
end 
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clear I 
res450cmpld=zeros( 42, I); 
forN=l:42 
x=['resid450s' int2str(N)]; 
res450cmpld(N)=eval(x); 
end 
clear x 
clearN 
res650cmpld=zeros( 42, 1 ); 
forN=l:42 
x=['resid650s' int2str(N)]; 
res650cmpld(N)=eval(x); 
end 
clear x 
clearN 
clear I 
for I=l:42 
X=['clear resid450s' int2str(I)]; 
eval(X); 
end 
clear I 
for I=l:42 
X=['clear resid650s' int2str(I)]; 
eval(X); 
end 
clear x 
clearN 
clear conc650 
clear conc450 
clear cholspec650 
clear linspec650 
clear totalspec 
clear X 
clear I 
clearN 
clear chol650 
clear kmat450 
clear kmat650 
clear lin650 
clear minuscholandlin 
clear name 
clear temp 
clear resid450 
clear resid650 
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APPENDIXB 
LSQNONNEG SCRIPT FOR SERUMS 
load kmat450.txt 
load kmat650.txt 
load lin650.txt 
load chol650.txt 
forN=l:19 
name=['s' int2str(N) '.txt']; 
load(name); 
end 
clearN 
clear name 
forN=l:19 
name=['s' int2str(N)]; 
conc650 = lsqnonneg(kmat650,eval(name)); 
X = conc650(6); 
cholspec650= X*chol650; 
X = conc650(1 ); 
1inspec650 = X*lin650; 
totalspec = cholspec650 + linspec650; 
minuscholandlin = eval(name) -totalspec; 
X=minuscholandlin(l :51 ); 
conc450 = lsqnonneg(kmat450,X); 
temp=['minuscholandlin650s' ,int2str(N), '= minuscholandlin']; 
eval(temp); 
temp=('conc650s' ,int2str(N), '= conc650']; 
eval(temp); 
temp=['conc450s' ,int2str(N), '= conc450']; 
eval(temp); 
temp=['cholspec650s' ,int2str(N), ' = cholspec650']; 
eval(temp); 
temp=['linspec650s' ,int2str(N), '= linspec650']; 
eval(temp); 
temp=['cholandlins' ,int2str(N), '= totalspec']; 
eval(temp); 
end 
forl=l:14 
X=['clear s' int2str(I)]; 
eval(X); 
end 
clear conc650 
clear conc450 
clear cholspec650 
clear linspec650 
clear totalspec 
clear X 
clear I 
clearN 
clear chol650 
clear kmat450 
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clear kmat650 
clear lin650 
clear minuscholandlin 
clear name 
clear temp 
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OSU WELLl~SS CENTER 
INFORMED CONSENT FORM 
BLOOD TESTING 
Explanation of Test 
· The blood test you are about to undergo is part of the Oklahoma State University 
Wellness Program. T.ne test includes selected blood variables analyzed from the 
fingerstick method or from a venous sample. 
It will be determined, prior to testing, that this test is appropriate and safe for you. 
All testing will be conducted by trained personnel and procedures will be explained to 
your satisfaction at the oUtSCt. 
Possible Risks 
The potential risks associated with the venipuncture/fingerstick are: (1) 
Venipuncture/fingerstick may cause some pain or discomfon. The exact amount, if any 
will be dependent upon individual preconceptions and pain threshold levels. (2) Possible 
hematoma (bruising) at the venipuncture/fingerstick site following the procedure. The 
occurrence or non-occurrence will be dependent upon bleeding/coagulation times and 
adherence to instructions penaining to holding a cotton ball against the 
venipuncture/fingerstick site, with pressure, for five minutes following extraction of the 
needle or following the fingerstick. (3) Slight risk of infection. Any break in the integrity 
of the skin is associated with a small degree of infection risk. However, if directions are 
followed the risk is very small. 
Consent by Subject 
Information. which is obtained in the health screening, will be treated as privileged and 
confidential. IF USED FOR STATISTICAL RESEARCH PURPOSES, INDIVIDUAL 
IDENTITIES WILL NOT BE RELEASED. IF RESULTS FROM THE RESEARCH 
ARE PUBUSHED, NO INDIVIDUALS WlLL BE NAMED m THE ANALYSIS OF 
TIIE DATA DATA will be statistica..lly analyzed in an aggregate manner. The Wellness 
Center professional/medical staff RESERVE THE RIGHT TO contact you if your results 
are outside normal REFERENCE limits for recommendations and educational 
opportunities. In addition, if indicated, a small amount of the blood drawn may be used 
for research in alternative cholesterol testing. 
I have read the foregoing, I understand it, and any questions which may have 
occurred to me have been answered to my satisfaction. 
Date _________ _ 
Subject Signature. _____________ _ 
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